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ABSTRACT 
 
The role of fibrin clot properties and fibrinogen nitration in the 
pathology of venous thromboembolism. 
 
Marissa Rose Martinez 
Harry Ischiropoulos, Ph.D. 
 
Deep vein thrombosis (DVT) and pulmonary embolism (PE) together comprise the 
disease state of venous thromboembolism (VTE). Thrombi in the veins of the lower 
extremities (DVT) can embolize, resulting in complete or partial occlusion of circulation 
through the pulmonary vasculature (PE). Despite a common etiology between DVT and 
PE, the cause of embolization remains mostly unknown. Research indicates that fibrin 
clot structure and functional properties are altered in VTE compared to healthy controls. 
Whether these properties differ between DVT and PE subjects remains to be determined, 
and may underscore possible mechanisms of embolization. Inflammation and oxidant 
production are involved in the pathogenesis of VTE. However, biomarkers documenting 
these pathways in humans are lacking. Elevated levels of nitrated fibrinogen have been 
documented during inflammatory and oxidative challenges and may serve as a functional 
biomarker in VTE. Differences in fibrin clot structure and functional properties between 
DVT and PE, as well as the role of nitrated fibrinogen as a biomarker of VTE were 
evaluated in the plasma of subjects presenting with symptoms of VTE to the emergency 
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department at the Hospital of the University of Pennsylvania. Plasma fibrin clots derived 
from PE subjects showed increased establishment of viscoelastic properties and faster 
lysis time compared with DVT. The rate and extent of factor XIIIa crosslinking of fibrin 
were similar between DVT and PE. Clots from PE subjects showed decreased fiber 
density and no differences in fiber bundling. Together these data suggests that fibrin 
fibers are formed faster in PE subjects, possibly resulting in earlier lysis, which may lead 
to instability and embolization. Nitrated fibrinogen levels were elevated in VTE positive 
compared to VTE negative subjects, with no differences in fibrinogen concentration.  
Subjects in the highest quartile of nitrated fibrinogen had an increased risk of VTE 
compared with the lowest quartile.  This risk persisted after univariate adjustment for 
advanced age, active cancer, and recent surgery, but not after multivariate adjustment for 
all variables.  Thus, nitrated fibrinogen is an oxidative risk marker in VTE, providing a 
novel mechanistic link between oxidant production, inflammation, and VTE.   
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CHAPTER 1 
Introduction 
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1.1 Introduction to VTE 
Venous thromboembolism (VTE) is a common thrombotic disease state that encompasses 
both deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is the formation 
of one or more thrombi within the body’s large veins, and is usually localized to the veins 
of the lower extremities. Production of these thrombi can result in partial or complete 
blockage of venous circulation.  As such, patients often present with symptoms and signs 
of pain, swelling, discoloration, and tenderness in the affected area. One of the most 
serious complications of DVT is PE, which occurs when the thrombus embolizes and 
becomes lodged within the pulmonary vasculature, partially or completely blocking a 
pulmonary artery or branch. In this way, DVT and PE are two disease states related by a 
common origin, which subsequently diverge due to distinct mechanisms that have yet to 
be determined. 
1.1.1 Prevalence of VTE 
VTE affects around 1 per 1000 people per year within the United States, with increasing 
incidence for congenital and acquired thrombophilic risk factors (Anderson et al., 1991). 
Using computer modeling, it is estimated that over 900,000 events of incident or 
recurrent, fatal and non-fatal VTE occur annually within the U.S., more than either 
myocardial infarction or stroke (Heit et al., 2005). History of DVT is itself a risk factor 
for a second episode, as 30 % of patients experience a recurrent event within 10 years, 
with the greatest risk within 6-12 months after the initial event (Heit et al., 2000a, 
Schulman et al., 2006).  Patients with recurrent VTE are also more likely to experience 
the same type of occurrence as the incident event (Schulman et al., 2006, Anonymous 
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1997). Thirty percent of VTE cases die within three months (Heit et al., 1999).  Although 
DVT is not a significant cause of death, a longitudinal study investigating the etiology of 
VTE found that 9 % of cases of DVT resulted in death (Cushman et al., 2004), and 
modeling for both hospital and community based DVT estimate that over 2200 deaths per 
year are attributed to DVT (Heit et al., 2005).  PE is the most significant cause for 
mortality within VTE, with epidemiological studies indicating that 23 % of patients die 
immediately from PE, and an additional 25 % die within 3.5 years (Anderson et al., 
1991).  Together, DVT and PE are estimated to account for between 100,000 and 180,000 
deaths each year within the United States (Rathbun., 2009). 
1.1.2 Pathophysiology of VTE 
The formation of thrombi in either the arterial or venous systems is due to aberrant 
activation of the coagulation system, likely due to some combination of changes in blood 
flow, endothelial activation or disruption, and a hypercoagulable state, as Virchow 
described (Virchow., 1856). Unlike arterial thrombosis, venous thrombosis occurs in the 
absence of endothelial denudation or apparent damage (Schaub et al., 1984, von Bruhl et 
al., 2012), suggesting that the other initiators of thrombosis described above, as well as 
participation from inflammatory mediators play a more central role in VTE pathology 
(Schaub et al., 1984, Sevitt., 1974). DVT often occurs in areas of stasis or disturbed 
blood flow such as in valve pockets or sinuses (Sevitt., 1974). To maintain quiescent 
conditions, endothelial cells produce and secrete factors that prevent cell adhesion and 
activation of coagulation, including thrombomodulin, protein C, prostacyclin, and nitric 
oxide. Although the central cause of VTE remains unknown it is clear that during VTE 
endothelial cells become activated resulting in the surface expression of adhesion 
 4 
proteins such as P-selectin and von Willibrand factor (von Bruhl et al., 2012, Myers et al., 
2002, Palabrica et al., 1992, Geng et al., 1990, Wakefield et al., 1995). Neutrophils and 
monocytes express P-Selectin Glycoprotein-1, and are subsequently recruited to P-
selectin expressing endothelial cells (von Bruhl et al., 2012, Myers et al., 2002, Palabrica 
et al., 1992, Geng et al., 1990, Wakefield et al., 1995). Upon binding to these proteins, 
neutrophils, and monocytes become activated and shed tissue factor bearing 
microparticles that contain anionic membranes capable of assembling the coagulation 
cascade complexes (Figure 1-1) (von Bruhl et al., 2012, von Bruhl et al., 2012, 
Hrachovinova et al., 2003, Biro et al., 2003, Jy et al., 1995). Ultimately, fibrin is formed 
in the last step of the coagulation cascade, producing a thrombus composed mainly of 
fibrin and leukocytes with some platelets and trapped erythrocytes (Schaub et al., 1984, 
von Bruhl et al., 2012, Sevitt., 1974, Palabrica et al., 1992, McGuinness et al., 2001). 
Alternatively in VTE, thrombi can also have two distinct cellular compositions. Thrombi 
near the site of initiation are red, composed mainly of erythrocytes and fibrin, and 
thrombi downstream of the initiation site are white, composed of mainly platelets and 
some fibrin (Sevitt., 1974).  The thrombus can fully or partially abrogate blood flow 
through the vein resulting in pain, swelling, and discoloration in the affected area.  
During and following thrombus formation, cellular factors work to resolve the thrombus, 
which resembles wound healing. The formation of fibrin, in either soluble or fiber form 
(Rakoczi et al., 1978, Garman and Smith., 1982, Thorsen et al., 1972), acts as a cofactor 
for tissue plasminogen activator (tPA) cleavage of the serine protease plasminogen, 
forming a ternary complex that produces plasmin and results in the degradation of the 
fibrin clot (Hoylaerts et al., 1982). Although leukocytes are capable of endothelial 
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damage during chemotaxis and subsequent diapedesis, they are also required for 
thrombus resolution (Stewart et al., 1974). Neutrophils are the first cells to invade the 
thrombus, and they function to degrade collagen and fibrin (Varma et al., 2003). Their 
depletion during thrombus resolution results in larger thrombi (Varma et al., 2003). 
Similar results are seen with macrophages where direct administration of peritoneal 
macrophages decreased thrombus size by more than fivefold and deletion of the 
monocyte attractant chemokine, CCR2, inhibited monocyte recruitment and thrombus 
resolution (Ali et al., 2006). 
Upon embolization, the thrombus can become lodged in a pulmonary artery or branch, 
with smaller thrombi traveling farther through the vasculature (Pryce and Heard., 1956). 
Large emboli can completely abrogate blood flow, and may result in death due to 
insufficient blood flow to fill the left side of the heart and maintain systemic arterial 
pressure (Corrin and Nicholson., 2011). Large and small emboli can both result in 
complete or partial infarction, which is necrosis of the tissue distal to the site of embolic 
obstruction. Complete infarction is rare and thought to require congestion in the lungs 
due to conditions such as heart disease (Dalen et al., 1977). Complete infarction can be 
healed by repair mechanisms similar to those described for DVT accompanied by the 
production of scar tissue (Corrin and Nicholson., 2011). Partial infarction is much more 
common and is characterized by edema, followed by capillary rupture and a filling of the 
alveoli with blood (Corrin and Nicholson., 2011). These infarcts are resolved within a 
few days, and usually little to no production of scar tissue is evident (Corrin and 
Nicholson., 2011).  
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Although the cause of embolization remains unknown, the location of the thrombus is 
associated with risk for PE. Deep veins of the lower extremities include the veins above 
the knee i.e. proximal and those veins below the knee or distal. Proximal veins include 
popliteal, femoral, or iliac and distal veins include tibial, peroneal, and the muscular calf 
veins, soleal and gemellar.  Distal DVT is rarely associated with symptoms (Ciuti et al., 
2012), while 88 % of patients with symptomatic DVT have thrombi localized to the 
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proximal veins (Cogo et al., 1993). Proximal, and not distal DVT, is frequently 
accompanied by PE (Moser and LeMoine., 1981). In one early study, PE occurred in 0 of 
31 subjects with distal DVT, whereas in subjects with proximal vein thrombosis, PE 
occurred in 4 of 9 subjects (Kakkar et al., 1969). Furthermore, in symptomatic DVT 
subjects without chest symptoms of PE, 40 % had evidence of PE upon lung scanning 
(Moser et al., 1994). Nearly 100 % of subjects with proximal DVT also had evidence of 
distal DVT, indicating that thrombosis starts in the calf veins and propagates to the 
proximal veins, whereby it may embolize.  
1.1.3 VTE diagnosis 
DVT is diagnosed by several imaging techniques, but the reference standard is contrast 
venography. To view the entire deep venous system, iodinated contrast agent is injected 
into the dorsal foot vein and lack of venous filling is an indicator of DVT (Bates et al., 
2012). Contrast venography is highly sensitive (95 %) and specific (92 %) (Killewich et 
al., 1989), but is expensive, invasive, and contraindicated in patients with renal disease 
and allergy to contrast media (Lensing et al., 1990). Thus, the utility of non-invasive 
diagnostic tests are preferentially used during diagnosis of DVT. Clinical probability 
scoring is used in the primary analysis of likely DVT and is recommended by the 
American College of Chest Physicians as the first assessment for diagnosis. Wells pretest 
probability scoring is the most widely used and takes into account signs, symptoms and 
risk factors for DVT and assigns a low, moderate or high probability (Wells et al., 1997). 
Following a low pretest probability, D-dimer testing is recommended.  D-dimers are a 
crosslinked fibrin degradation product produced during the intravascular thrombosis and 
thrombolysis (Figure 1-1) (Ruckley et al., 1970). Several assays have been developed for 
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the rapid measurement of these products in both plasma and blood. These include 
qualitative assays such as whole blood agglutination (John et al., 1990) and quantitative 
assays such as latex agglutination (Elms et al., 1986), and enzyme-linked immunosorbent 
(ELISA) or immunofluorescence (ELFA) assays (Whitaker et al., 1985). Agglutination 
assays rely on monoclonal anti-D-dimer antibody linked red blood cells or latex beads 
that aggregate in the presence of antigen (D-dimer) (Elms et al., 1986). The ELISA and 
ELFA assays also utilize monoclonal anti-D-dimer antibodies in a multi-well format 
coupled with either chemiluminescence or fluorescence detection (de Moerloose et al., 
1996, Bounameaux et al., 1991). Compared to latex (57-100 %) and whole blood 
agglutination (53-100 %), ELISA (71-100 %) and ELFA (88-100 %) have the highest 
sensitivity. Specificity remains low in all tests (Di Nisio et al., 2007), which is partly 
attributed to the high number of non-thrombotic conditions, including pregnancy, cancer, 
infection etc. (Francalanci et al., 1995, Hafter et al., 1985, Kuller et al., 2008) that also 
suffer from increased D-dimer levels. Because of this, D-dimer is used as an exclusionary 
test, with patients below a certain D-dimer level precluded from VTE. Recent efforts 
have been made to identify additional markers of VTE to aid in non-invasive diagnosis, 
including coagulation and inflammatory factors such as factor XI, c-reactive protein, and 
myeloperoxidase (MPO) (Cushman et al., 2009, Kucher et al., 2003b, Nordenholz et al., 
2008, Mitchell et al., 2008, Martinez et al., 2012). Studies on MPO have shown that 
elevated MPO is not only is a risk factor for VTE, but moderately improves upon the 
specificity of D-dimer for VTE diagnosis (59 % vs. 73 %) (Nordenholz et al., 2008, 
Mitchell et al., 2008). Nonetheless, identification of additional markers of VTE may help 
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explain the underlying etiology or pathology of VTE, and may also prove to be useful in 
future diagnostic marker of the disease. 
Due to its non-invasive nature and high accuracy, the most commonly used imaging 
modality for DVT diagnosis is ultrasound (US). Distal DVT is not usually associated 
with PE or other clinically adverse events, and thus compression US (CUS) is often used 
and focused primarily on the proximal veins such as femoral and popliteal. The inability 
to collapse the vein under pressure is indicative of DVT by CUS (Bates et al., 2012), 
which has a high sensitivity (97 %) and specificity (86 %) (Heijboer et al., 1992). For 
patients diagnosed with distal DVT, it is often recommended that the patient receive 
additional follow-up US 5-7 days following the initial US to ensure that thrombosis has 
not extended to the proximal veins (Bates et al., 2012).  
Both clinical probability scoring and D-dimer levels are also used as initial non-invasive 
tests for PE diagnosis. A high or moderate likelihood of PE requires subsequent use of 
imaging, of which computed tomographic pulmonary angiography (CTPA) is the 
accepted standard of care. In CTPA the patient receives an iodinated contrast agent that, 
upon scanning will show filling, or in the case of embolism, a defect in filling of the 
pulmonary vessels. A recent meta-analysis indicates that sensitivity of CTPA alone is 
comparable to CTPA plus additional CUS in identifying PE (97.4 % with vs. 97.3 % 
without CUS) (Mos et al., 2009). This study also demonstrated high negative predictive 
value (98.8 %) for CTPA indicating that overall, CTPA alone is sufficient to accurately 
identify positive and negative PE patients (Mos et al., 2009). 
1.1.4 Antithrombotic therapy for VTE 
 10 
Treatment modalities are similar for DVT and PE patients.  Therapy for VTE targets the 
coagulation cascade, supporting a main role for fibrin rather than platelets in VTE. 
Heparin is a standard first line treatment for acute VTE. It functions to bind and activate 
antithrombin III causing a conformational change, which results in the inhibition of 
thrombin, factor IXa, and factor Xa (Figure 1-1) (Chuang et al., 2001). Heparin is a 
heterogeneous mixture of highly sulfated glycosaminoglycans and comes in two main 
types, unfractionated heparin (UFH), which is composed of polysaccharides ranging in 
size from 5-40 kDa and low molecular weight heparin (LMWH), which contains only 
polysaccharides equal to or less than 8 kDa (Lane et al., 1979). Homogenous 
polysaccharides such as fondaparinux function in a similar manner to the other heparin 
derivatives, but are less frequently used due to cost. UFH and LMWH have both been 
shown to resolve acute thrombosis and prevent recurrent VTE to similar degrees (Kearon 
et al., 2006), but LMWH has decreased risk for osteoporosis and heparin-induced 
thrombocytopenia (Monreal et al., 1994, Martel et al., 2005), and thus is recommended as 
initial antithrombotic treatment in VTE (Kearon et al., 2012) . Initial therapy for VTE 
usually proceeds for 5-10 days followed by long-term therapy for 3-6 months. The goal 
of long-term therapy is the complete resolution of the thrombus during the initial episode 
of VTE and to prevent recurrence. During this phase of treatment, patients are usually 
switched to vitamin K antagonists such as warfarin. Warfarin inhibits the enzyme vitamin 
K epoxide reductase, preventing vitamin K production (Magnusson et al., 1974). The 
coagulation factors VII, IX, X, prothrombin, protein S, and protein C require vitamin K 
for the conversion of glutamic acid to γ-carboxyglutamic acid, which is essential for 
calcium binding of phospholipid membranes (Furie et al., 1979). Continuation of therapy 
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past 6 months may be required in those where the risk of VTE remains either unknown as 
in idiopathic VTE, or ongoing as in cancer (Kearon et al., 2012). Patients with proximal 
DVT or PE are recommended for treatment as described above. However, patients with 
distal DVT without indication of risk factors for extension to proximal DVT are not 
recommended for treatment due to the high risk of bleeding outweighing benefits of 
anticoagulant therapy (Kearon et al., 2012). 
1.2 Fibrinogen and clot formation 
Fibrinogen is a 340 kDa protein involved in the end steps of the coagulation cascade 
(Figure 1-2). It is produced in liver hepatocytes and secreted into the blood (Whipple and 
Hurwitz., 1911), where it circulates with a half-life of about 3 days (Stein et al., 1978). 
Fibrinogen is composed of two pairs of three non-identical chains termed Aα, Bβ, and γ. 
Each chain is encoded by a different gene, all of which reside on chromosome 4 (Kant et 
al., 1983, Crabtree and Kant., 1982, Olaisen et al., 1982, Humphries et al., 1984). 
Together the chains comprise a symmetrical molecule composed of one globular E region 
flanked on each side by globular D regions (D-E-D) (Figure 1-2) (Hall and Slayter., 1959, 
Kollman et al., 2009, Yang et al., 2001, Brown et al., 2000). The central E region is 
connected to each of the D regions by triple helical coiled-coils comprised of the Aα, Bβ, 
and γ chains (Figure 1-2) (Kollman et al., 2009, Yang et al., 2001, Brown et al., 2000). 
The chains are held together by 5 symmetrical disulfide bonds and an asymmetrical 
disulfide ring (Blomback et al., 1976, Huang et al., 1993). The N-termini of the Aα, Bβ, 
and γ chains are all located in the E region and comprise the central nodule (Blomback et 
al., 1976, Zhang and Redman., 1992). The D regions are comprised of β and γ nodules 
formed from the carboxy terminal portions of the β and γ chains, respectively (Figure 1-
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2) (Yee et al., 1997). The carboxy terminal portion of the α chain contains an 
independently folded compact domain called the αC domain (Burton et al., 2007) that is 
tethered amino terminally to a flexible region termed the αC connector (Tsurupa et al., 
2002, Medved et al., 1983). The αC region and connector are hypothesized to be highly 
flexible and unable to be crystalized. Thus, they are not represented in Figure 1-2. The N-
termini of Aα and Bβ chains contain fibrinopeptides A (FpA) and B (FpB) (Figure 1-3) 
(Kollman et al., 2009, Yang et al., 2001, Brown et al., 2000). Thrombin cleavage of these 
peptides exposes ‘A’ and ‘B’ knobs, resulting in the formation of fibrin monomers 
(Lorand., 1951, Blomback et al., 1978, Blomback et al., 1972, Bettelheim., 1956, 
Budzynski et al., 1983). ‘A’ and ‘B’ knobs are positively charged and have 
complementary negatively charged binding sites within the γ and β nodules in the D 
region of adjoining monomers termed ‘a’ and ‘b’ holes (Figure 1-3) (Pratt et al., 1997, 
Spraggon et al., 1997). Knob-hole associations each result in the formation of half-
staggered, double stranded protofibrils (Krakow et al., 1972, Fowler et al., 1981), which 
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then associate laterally to form fibrin fibers (Krakow et al., 1972, Hewat et al., 1983) and 
a branching network (Hantgan and Hermans., 1979). The number of protofibrils as well 
as the number of aggregated fibers together determine fiber diameter (Weisel., 1986, 
Weisel and Nagaswami., 1992). FpA release occurs at a faster rate than FpB (Blomback 
et al., 1976, Nossel et al., 1974) and thus, A:a interactions largely dictate fibrin 
polymerization rates.  FpB release is not required for fibrin polymerization, but B:b 
interactions do function to align D-regions during polymerization, contributing to lateral 
aggregation and fiber formation, and also preventing the dissociation of protofibrils 
(Blomback et al., 1978, Shainoff and Dardik., 1983). As a consequence, in the absence of 
FpA release, B:b interactions alone result in thicker fibers and a more porous structure 
(Mosesson et al., 1987).  
1.2.1 Factor XIII and fibrin crosslinking 
Factor XIII (FXIII) is a transglutaminase that crosslinks fibrin subunits, providing 
stability and elasticity to the clot (Figure 1-1) (Gerth et al., 1974, Brown et al., 2009, 
Lorand and Jacobsen., 1962, Collet et al., 2000). FXIII is a heterotetrameric protein 
composed of two sets of A and B homodimeric domains (Schwartz et al., 1971). The A 
domains function as carriers of the B domains (Chung et al., 1974), which are activated 
by thrombin through cleavage of the N-terminal activation peptide (Nakamura et al., 
1975). Activated FXIII crosslinks fibrin via the formation of ε-(γ-glutamyl) lysine bonds 
between γ-Gln
398 
and γ-Lys
406
 on each of the γ chains (Wang., 2011), creating γ-dimers. 
α-polymer crosslinks are formed primarily between α-Gln
328
, α-Gln
366
 and α-Lys
556
 and 
α-Lys
580
 (Sobel and Gawinowicz., 1996, Cottrell et al., 1979). α-γ heteropolymers are 
also formed with γ-Lys
406
 and α-Gln
328
 and/or α-Gln
366
 (Sobel and Gawinowicz., 1996). 
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1.2.2 Fibrinolysis 
tPA is a serine protease involved in fibrinolysis. The main function of tPA in hemostasis 
is to activate the zymogen precursor, plasminogen by cleavage of Arg
561
-Val
562
, 
generating the active serine protease, plasmin (Robbins et al., 1967). This occurs when 
tPA binds to fibrin at sites Aα
148-160 
and γ
312-324
, which are exposed during fibrin 
polymerization (Schielen et al., 1991a, Schielen et al., 1991b). Subsequently, 
plasminogen is recruited and forms a ternary complex with tPA and fibrin, which 
increases the catalytic efficiency of tPA activation of plasminogen to plasmin (Hoylaerts 
et al., 1982). Both tPA and plasminogen have preferential binding to fibrin over 
fibrinogen (Hoylaerts et al., 1982) preventing unwarranted degradation of fibrinogen in 
circulation. Plasmin binds and cleaves fibrin at high-affinity lysines located in the αC 
region (Bok and Mangel., 1985, Tsurupa and Medved., 2001), subsequently exposing 
additional lysine residues that plasmin further cleaves into smaller fragments (Bok and 
Mangel., 1985). Plasmin cleavage produces fibrin degradation products of various sizes 
and compositions, most notably X, Y, D, D-dimer, and E (KOPEC et al., 1973, Gaffney 
et al., 1980). Endogenous inhibitors of fibrinolysis target both tPA and plasmin, and 
include plasminogen activator inhibitor-1 (PAI-1), α2-antiplasmin (α2-PI), and thrombin-
activatable fibrinolysis inhibitor (TAFI). FXIII, while not an actual inhibitor of 
fibrinolysis, does reduce fibrinolytic potential by crosslinking of fibrin fibers as well as 
crosslinking α2-PI to fibrin fibers (Lorand and Jacobsen., 1962, Gormsen et al., 1967).  
1.2.3 Fibrin clot structure and functional properties in thrombotic disease 
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The role of the clot and its components has been evolutionarily optimized to prevent 
bleeding and maintain hemostasis. However, many environmental and genetic factors can 
predispose the clotting process towards a prothrombotic phenotype (Uitte de Willige et 
al., 2005, Parastatidis et al., 2008). Furthermore, many studies have suggested that 
changes due to factors such as plasma constituents, fibrinogen variants and post-
translational modifications affect fibrin clot structure and functional properties and 
present as thrombotic risk factors (Parastatidis et al., 2008, Konings et al., 2011, Gersh et 
al., 2009). In general, fibrin clot structures with increased fiber density, decreased fiber 
diameter, and decreased porosity have generally been associated with diminished lysis 
(Collet et al., 2000) and are considered as a risk factor for thrombosis (Collet et al., 
2006). Although individual thin fibers are lysed faster than thicker fibers, clots that are 
composed of thin fibers with increased fiber density lyse more slowly than clots 
composed of thick fibers of decreased fiber density (Collet et al., 2000). This is likely due 
to the lateral transection of plasmin across fibers rather than uniform digestion from the 
outside in of a fiber (Collet et al., 2000). Also, tPA is a limiting constituent during lysis, 
and clots with decreased fiber density have a higher tPA to fiber ratio, resulting in 
increased lysis (Bannish et al., Accepted b, Bannish et al., Accepted a). Denser clots also 
tend to have increased elastic (G’) and viscous (G”) properties (Collet et al., 2006, 
Roberts et al., 1974, Ryan et al., 1999), which are measures of stiffness and 
deformability, respectively.  These two properties may be especially important with 
regards to embolization. Within the vessel, blood flow exerts shear stress on the 
thrombus. Clots that are less capable of withstanding those shear forces may be more 
amenable to embolization. It is unclear whether clots that are stiffer would be more or 
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less likely to embolize, as increased stiffness might impart stability or strain-hardening 
and brittleness.  Similarly, clots that are more viscous may deform better under shear or 
might be very unstable and friable.  
1.2.3.1 Fibrin clot properties in arterial disease 
Previous studies investigating the effects of fibrin clot structure and functional properties 
have mainly focused on arterial thrombotic diseases. Compared to healthy age-matched 
controls, clots derived ex vivo from the plasma of subjects with premature CAD with a 
past history of acute coronary syndrome, exhibited increased fiber density, decreased 
porosity, fiber diameter and length. Plasma clots from these subjects also exhibited 
increased final clot stiffness and diminished clot lysis (Collet et al., 2006). Fibrin clot 
stiffness and length were independently correlated with both lysis and CAD, providing 
further evidence that clot structure is related to both functional properties and disease 
risk. In addition, recent studies have shown that plasma fibrin clot structure and 
functional properties are related to in vivo thrombus composition. In 45 ST-segment 
elevation myocardial infarction subjects both thrombus structure, including fibrin, 
cholesterol, and cellular components, as well as plasma fibrin clot properties were 
measured (Silvain et al., 2011). The structural components measured from in vivo-excised 
thrombi correlated with clot properties derived from ex vivo created plasma clots, 
including the elastic component and lysis time. In addition, fibrin was a main component 
of the thrombus (60 %) and was positively correlated with ischemic time. These data 
support the relevance of ex vivo plasma clots structure and functional properties with 
relation to thrombotic pathology. 
 18 
1.2.3.2 Fibrin clot properties in venous thromboembolic disease  
Fibrin clot properties have begun to be evaluated in VTE. In a recent study, VTE subjects 
showed diminished lysis and decreased clot permeability compared to healthy controls 
(Lisman et al., 2005, Undas et al., 2009), similar to what has been shown in CAD (Collet 
et al., 2006). In a sub-analysis of the data, the authors also show that PE subjects have 
enhanced clot lysis and increased permeability compared to DVT subjects (Undas et al., 
2009). These data suggest that fibrin clot structure and functional properties may be 
different between DVT and PE patients. Because DVT and PE share a common 
pathogenesis with divergent outcomes, identifying differential clot properties may 
underscore the mechanisms that regulate embolization.  
1.3 Production of reactive oxygen and nitrogen intermediates in inflammation 
Reactive oxygen and nitrogen intermediates are produced during inflammatory processes. 
This includes the production of superoxide (O2·
-
) by the enzymes NADPH oxidase and 
xanthine oxidase, located in neutrophils and endothelial cells, respectively (McCord and 
Fridovich., 1968, Babior et al., 1976). Superoxide can undergo dismutation reaction by 
superoxide dismutase, generating hydrogen peroxide (H2O2) and water (McCord and 
Fridovich., 1969, Klug et al., 1972). Hydrogen peroxide can be reduced to the more 
potent oxidant, hydroxyl radical (·OH) and hydroxide ion (OH
-
) by Fe (II) through 
Fenton chemistry (Fenton., 1894), or oxidized to hypochlorous (HOCl) or hypobromous 
(HOBr) acids by peroxidase enzymes located in leukocytes (van Dalen et al., 1997, 
Klebanoff and Shepard., 1984).  
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The small, free radical, gaseous molecule, nitric oxide (·NO) is produced constitutively 
by many cell types, but also at heightened levels in response to inflammation (Furchgott 
and Zawadzki., 1980, Furchgott and Bhadrakom., 1953, Ignarro et al., 1987, Palmer et 
al., 1987). Nitric oxide can react with other free radicals including superoxide to produce 
the potent oxidant, peroxynitrite (ONOO
-
) and its conjugate acid, peroxynitrous acid 
(ONOOH) (Reaction 1) (Gryglewski et al., 1986, Beckman et al., 1990). Peroxynitrous 
acid can undergo homolytic fission to generate hydroxyl radical and nitrogen dioxide 
(·NO2) (Reaction 2) (Beckman et al., 1990), which are capable of oxidation and nitration 
of proteins and lipids (Prutz et al., 1985). Despite this, it is more likely that under 
physiological conditions (Beckman et al., 1990) peroxynitrite reacts with the high levels 
of dissolved carbon dioxide (1-5 mM) to form the intermediate nitrosoperoxycarbonate 
(ONOOCO2
-
) (Reaction 3) (Gow et al., 1996, Lymar and Hurst., Denicola et al., 1996). 
The homolytic cleavage of this intermediate produces nitrogen dioxide and carbonate 
radical (CO3·
-
) (Reaction 4) (Goldstein and Czapski., 1999), which are also capable of 
nitration and oxidation reactions. Peroxidases such as MPO and eosinophil peroxidase are 
also able to oxidize nitrite, producing the nitrative intermediate, nitrogen dioxide (van der 
Vliet et al., 1997). 
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1.3.1 Modifications of tyrosine residues by nitrative species 
The peroxidase/nitrite pathway or nitrosoperoxycarbonate decomposition result in the 
formation of nitrogen dioxide as described above.  In one proposed mechanism of 
nitrotyrosine formation, tyrosyl radical is produced by oxidation of tyrosine by either 
nitrogen dioxide, hydroxyl radical, or carbonate radical, in the case of 
nitrosoperoxycarbonate decomposition (Santos et al., 2000). Subsequently, radical-
radical recombination by tyrosyl radical and nitrogen dioxide produce nitrotyrosine 
(Figure 1-4) (Prutz et al., 1985). 
Not all tyrosines are capable of becoming nitrated. The secondary protein structure is an 
important determinant of which tyrosines become modified.  Surface exposure of the 
tyrosine residue, location of the tyrosine within a loop structure, proximity to negative 
charges, and proximity to metal centers aid in the specificity of tyrosine nitration (Souza 
et al., 1999).  The physiologic and pathologic yields of nitration are low (10-100 μmol 
nitrotyrosine/ mol tyrosine), corresponding to 1 to 10 tyrosines nitrated for every 100,000 
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(Parastatidis et al., 2008, Brennan et al., 2002, Shishehbor et al., 2003). Because of this 
low yield, the biological significance of tyrosine nitration has been questioned. Often, 
post-translational modification of a protein that results in a loss of function requires a 
significant percentage of protein molecules to be modified. However, several proteins 
exhibit gain of function effects upon nitration, including actin and fibrinogen (Parastatidis 
et al., 2008, Aslan et al., 2003, Vadseth et al., 2004). Interestingly, both proteins are 
involved in polymerization reactions. Here, the addition of a few modified protein 
molecules enhances protein-protein interactions, and greatly affects the rate of 
polymerization (Parastatidis et al., 2008, Aslan et al., 2003, Vadseth et al., 2004). In 
fibrinogen, Tyr
292
 and Tyr
422
 were found to be nitrated in the plasma of smokers. These 
residues are located in the carboxyl termini of the β chains of fibrinogen near holes 'b’ 
and nitration may function to enhanced lateral aggregation (Parastatidis et al., 2008). 
Elevated nitrated fibrinogen levels increased the rate of fibrin polymerization and were 
positively correlated with the clot viscoelastic properties, elastic and viscous moduli, and 
inversely correlated with fibrinolysis rate (Parastatidis et al., 2008). These clots also 
exhibited increased fiber density and fiber clustering. Thus, nitration of a few protein 
molecules can indeed affect protein function and may have significant biological 
consequences. 
1.3.2 Tyrosine nitration plays a role in inflammation 
Leukocytes are key mediators of the immune response against foreign pathogens, but also 
play a role in chronic disease states such as atherosclerosis and VTE.  Neutrophils, 
monocytes and macrophages all contain the enzyme MPO. In neutrophils, MPO is 
localized to azurophilic granules, and in monocytes and macrophages it is localized to 
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lysosomal granules (Nichols et al., 1971, Bos et al., 1978). Upon activation, these 
leukocytes degranulate and release MPO into the extracellular space (Leffell and 
Spitznagel., 1974). MPO catalyzes the reduction of hydrogen peroxide, followed by the 
oxidation of halides (Cl
-
, Br
-
) to produce hypochlorous and hypobromous acids (van 
Dalen et al., 1997, Klebanoff and Shepard., 1984). These acids function as oxidants 
aimed at killing foreign pathogens. In addition, these cells produce nitric oxide through 
the both the constitutive and inducible forms of nitric oxide synthase (Wallerath et al., 
1997), and are capable of producing the oxidative post-translational modification, 
nitrotyrosine through MPO oxidation of nitrite (NO2
-
). Nitrotyrosine has classically been 
a hallmark of peroxynitrite formation. However, more recent studies also indicate MPO 
as a key producer of nitrotyrosine. In an inflammatory challenge model of C. albicans 
administration, nitrotyrosine formation was markedly increased in wild-type, but not 
MPO
-/- 
mice (Brennan et al., 2002). Neutrophils activated with 12-D-
tetradecanoylphorbol-13-acetate released MPO from their granules, which subsequently 
transcytosed to the subendothelial matrix, colocalizing with and nitrating fibronectin 
(Baldus et al., 2001). This effect was absent in enoxaparin treated mice, which prevented 
MPO transcytosis. Thus, the release of MPO into the extracellular space may serve as a 
mechanism by which circulating proteins become nitrated. 
The production of reactive oxygen and nitrogen species in inflammation has been 
extensively studied, and nitrotyrosine has been identified as both a marker and a 
functional modifier of proteins during inflammatory processes. In one study, 
lipopolysaccharide was administered to healthy human subjects and resulted in increased 
production of protein mediators of inflammation TGF-β, c-reactive protein, and MPO 
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(Heffron et al., 2009). Nitrated fibrinogen was also increased in this challenge model, 
peaking at 72-hrs post-injection, much later than the other inflammatory mediators. In 
addition, nitration of fibrinogen post-LPS injection resulted in increased rate of clot 
formation. This study implies that 1) nitration results as a direct consequence of 
inflammatory challenge, 2) nitrating intermediates are produced for prolonged periods of 
time following insult, and 3) tyrosine nitration effects protein function, specifically 
fibrinogen, which provides further evidence for the role of inflammation in thrombotic 
disorders. 
Peroxynitrite has been extensively studied and found to play a role in inflammatory 
processes, including, but not limited to the nitration of protein tyrosine residues. In 
response to cellular activation, peroxynitrite is produced by endogenous nitric oxide 
formation in macrophages (Ischiropoulos et al., 1992).  Peroxynitrite can inhibit cellular 
respiration in macrophages, producing DNA double-strand breaks, resulting in 
cytotoxicity associated with macrophage infiltration during inflammation (Szabo and 
Salzman., 1995). Peroxynitrite also activates Erk through the MAP kinase pathway, 
resulting in increased expression of αMβ2 on neutrophils and induces integrin dependent 
adhesion of neutrophils to endothelial cells (Zouki et al., 2001). Some studies have 
suggested that nitric oxide released from endothelial cells into the vascular lumen can 
interact with superoxide produced by activated neutrophils, producing peroxynitrite 
(Sohn et al., 2003). This could result in the production of nitrated and oxidized proteins 
within vascular circulation or in close proximity to the site of neutrophils or possibly 
macrophages.  
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Monoclonal and polyclonal antibodies to nitrated proteins, peptides and nitrotyrosine 
have been produced in mice and rabbits (Heijnen et al., 2006). This suggests that in vivo 
nitrotyrosine may be a target for endogenously produced anti-nitrotyrosine antibodies. 
Indeed, antibodies have been detected that recognize nitrated epitopes in acute lung 
injury, as well as in atherosclerotic lesions and the circulation of CAD patients (Thomson 
et al., 2007). Furthermore, in lymphoid tissues, antigen presenting cells displayed nitrated 
peptides by MHC class II molecule I-A, eliciting a CD4 T-cell response (Herzog et al., 
2005). This indicates that the production of nitrotyrosine elicits an immune response in 
acute lung injury and CAD, and may have indications in other diseases where nitrated 
proteins have been identified, such as VTE. 
1.3.3 Tyrosine nitration in VTE 
VTE is a thrombotic disease mediated by inflammation. Neutrophils and monocytes 
home to activated endothelial cells and are primary constituents of the thrombus in VTE 
(von Bruhl et al., 2012, Myers et al., 2002, Palabrica et al., 1992, Geng et al., 1990, 
Wakefield et al., 1995). As described above, these cells are capable of producing nitrating 
intermediates and thus may function as cellular sources of tyrosine nitration. 
Proinflammatory cytokines such as IL-1β and TNFα are increased during VTE (Reitsma 
and Rosendaal., 2004) and are also known to induce nitric oxide expression either 
through eNOS or iNOS in endothelial or inflammatory cells (Busse and Mulsch., 1990). 
Thus, the over production of nitric oxide may facilitate its conversion to a nitrating 
intermediate. Studies with LPS injection into humans, an inflammatory process mediated 
by neutrophils and monocytes (Rivers et al., 1975, Boggs et al., 1968), produces 
increased levels of nitrated fibrinogen (Heffron et al., 2009). Furthermore, other 
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inflammatory thrombotic conditions, such as CAD and those at risk for thrombotic 
disease, like smokers have elevated nitrated fibrinogen levels within their respective 
patient population (Parastatidis et al., 2008, Vadseth et al., 2004). Thus, VTE patients 
may exhibit increased nitrated fibrinogen levels during acute thrombosis, which may 
represent a novel biomarker for VTE.  
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1.4 Specific Aims 
Aim 1: Evaluate clot structure and functional properties in DVT and PE subjects, 
specifically focusing on those properties that might be involved in embolization.  
Hypothesis: PE subjects exhibit unique clot structure and functional properties 
separate from DVT that that lead to instability and embolization. 
DVT and PE are two pathological manifestations of the same disease, VTE. Thus far, the 
cause of embolization remains unknown. Research indicates that fibrin clot structure and 
functional properties are involved in both arterial and venous thrombotic disease and 
represent risk factors with pathological consequences. Furthermore, these properties may 
affect the ability of the clot to withstand shear forces within the vessel wall. Properties 
that are likely to be involved in embolization including viscoelastic properties, clot 
formation and lysis time, FXIII crosslinking and clot structure will be evaluated towards 
this end. Identification of differences in structure and functional clot properties between 
DVT and PE subjects may elucidate the mechanisms that regulate embolization. 
 
Aim 2: Measure nitrated fibrinogen levels in VTE subjects, evaluating its role as a 
biomarker and risk factor for VTE. 
Hypothesis: Nitrated fibrinogen levels are elevated in VTE, representing a unique 
marker of oxidative stress, inflammation, and coagulation in VTE.  
VTE is a thrombotic disease characterized by activation of the coagulation cascade, 
production of inflammatory mediators, and the generation of oxidative and nitrative 
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intermediates. Thus far, specific markers of these processes in VTE are lacking. Previous 
studies have identified nitrated fibrinogen as not only a marker of these processes in CAD 
and smokers, but also involved in alterations in clot structure and function. Herein we 
evaluate the role of nitrated fibrinogen as a unique biomarker in VTE with specific 
pathological relevance to the disease. 
 
. 
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CHAPTER 2 
 
Increased fibrinolysis and acquisition of fibrin clot viscoelastic 
properties are associated with pulmonary embolism. 
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2.1 Abstract 
Pulmonary embolism (PE) is a complication of deep vein thrombosis (DVT), although 
the cause of embolization remains relatively unknown. Fibrin clot structure and 
functional properties have been implicated in the pathology of venous thromboembolism.  
However, previous studies investigating the differences in properties between DVT and 
PE subjects remain incomplete. The goal of this study was to specifically evaluate fibrin 
properties that may contribute to embolization. Clot formation and lysis time, viscoelastic 
properties, activated factor XIII (FXIIIa) crosslinking, and clot structure were measured 
in the plasma from subjects with acute isolated DVT or PE. Clot formation and lysis time 
curves revealed faster lysis time in PE subjects, with no difference in lag time, rate of clot 
formation, or maximum absorbance. Compared with DVT, clots derived from PE 
subjects showed accelerated establishment of viscoelastic properties, documented by a 
decrease in lag time and an increase in the rate of viscoelastic property formation. Rate 
and extent of fibrin FXIIIa crosslinking were similar between DVT and PE subjects.  
Plasma fibrin clots from PE subjects exhibited lower fiber density compared to DVT.  
These data show that clot structure and functional properties differ between DVT and PE 
subjects, and may provide insights into possible mechanisms that regulate embolization. 
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2.2 Introduction 
Deep vein thrombosis (DVT) is a thrombotic disease that mainly affects the large veins of 
the lower extremities and pelvis. DVT can result in partial or complete occlusion of 
venous circulation. One of the most serious complications of DVT is pulmonary 
embolism (PE), which occurs when whole or part of the thrombus embolizes and 
becomes lodged within the pulmonary vasculature, partially or completely blocking a 
pulmonary artery or branch. Together, DVT and PE comprise the thrombotic disease, 
venous thromboembolism (VTE). In contrast to DVT, death is a common outcome in PE 
and has been estimated to account for an in-hospital case fatality rate of 23 % (Anderson 
et al., 1991). Despite a common pathology relating PE to DVT, a cause for embolization 
remains unknown. Evidence does suggest however, that the specific location of the 
thrombus in DVT is related to risk of PE. Subjects with distal vein thrombosis, i.e. those 
with thrombi localized to only the calf veins, are at very low risk of PE (Moser and 
LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994). This is in contrast to those with 
proximal vein thrombosis or thrombi above the knee, who are at high risk for having or 
developing PE (Moser and LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994).    
Recent research has focused on the relationship between fibrin clot structure and 
functional properties in relation to arterial thrombosis (Collet et al., 2006). Plasma clots 
derived ex vivo from subjects with premature coronary artery disease exhibited increased 
clot elastic properties, slower lysis, and increased fiber density compared to healthy 
controls (Collet et al., 2006). The authors further showed that clot structure and 
functional properties were associated with slower lysis and coronary artery disease. 
Although most similar studies have focused on arterial thrombosis (Silvain et al., 2011, 
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Vadseth et al., 2004, Machlus et al., 2011), some recent efforts have turned to venous 
thromboembolism (VTE) (Undas et al., 2009). Plasma clots from VTE subjects exhibited 
slower clot lysis time and decreased permeability as compared to relatives without 
disease and healthy controls. A sub-analysis of the data also showed that within the VTE-
positive population, PE subjects had clots with increased porosity and exhibited faster 
lysis rates compared to DVT subjects (Undas et al., 2009). This data indicates that in 
VTE, clot structure and the resultant functional properties may be associated with 
thrombosis and embolization.  
The goal of this study was to further investigate the relationship between fibrin clot 
structure and functional properties, expanding on the work by Undas et al. Specifically, 
this work evaluated for the first time the viscoelastic properties, clot formation and lysis 
time, and factor XIIIa crosslinking of fibrin employing plasma clots derived ex vivo from 
acute isolated DVT and PE subjects. Moreover, scanning electron microscopy was used 
to evaluate fiber clusters, bundles, density, and heterogeneities in fiber structure between 
plasma clots from acute isolated DVT and PE subjects. Differences in the establishment 
of viscoelastic properties and lysis time may contribute to embolization in PE subjects 
and provide additional insights into the pathways that contribute to pathology in VTE. 
2.3 Materials and Methods 
We performed a prospective cohort study from January 2010 to March 2012 of subjects 
18 years of age or older presenting to the Hospital of the University of Pennsylvania 
emergency department with suspected acute DVT or PE. Exclusion criteria included 
history of VTE within the prior 4 weeks, unavailable for 90 day follow-up, current use of 
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anticoagulants, including any low molecular weight heparins or warfarin, and inability to 
provide informed consent. DVT was diagnosed by compression ultrasonography and PE 
by computed tomographic pulmonary angiography. Subjects with negative imaging were 
contacted by telephone 90 days after enrollment to confirm that they did not develop 
clinically apparent VTE. Those who reported development of VTE over this interval 
despite initial negative imaging were also considered positive for DVT and/or PE.  
Subjects with both distal and proximal vein thrombosis were classified as proximal since 
DVT is thought to progress from a distal to proximal location, whereby it is more likely 
to embolize (Kakkar et al., 1969). Subjects diagnosed with both DVT and PE were 
classified as PE, since a majority of PE cases are thought to arise from DVT (Hull et al., 
1983). Three DVT subjects in our population reported a prior history of PE. These 
subjects were not excluded from the study as previous research has shown that 40 % of 
DVT subjects without chest symptoms of PE have evidence of PE upon lung scanning 
(Moser et al., 1994). Inclusion of these three subjects should bias our analysis towards the 
null hypothesis, and thus should not account for any observed differences in functional 
properties or structure. Secondary variables were also collected including demographic 
information, thrombotic risk factors, comorbidities, and medications. Prior to initiation of 
anticoagulant therapy, blood was collected from subjects in 3.2 % sodium citrate (BD 
Vacutainer, Franklin Lakes, NJ), and platelet poor plasma was prepared as described 
previously (Martinez et al., 2012) and stored at -80 °C. Due to sample volume 
limitations, not every patient sample was included in every assay. Because we 
hypothesized that functional properties would provide the most insight into the 
mechanisms that govern embolization, viscoelastic properties and clot formation and 
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lysis time assays were given priority for sample analysis. All samples available were used 
for these two assays. Samples for FXIIIa and SEM analysis were chosen at random, and 
do not differ in demographic variables or medication use compared with the full study 
population. The study design was approved by the Institutional Review Board Involving 
Human Subjects at the University of Pennsylvania and written informed consent was 
obtained from all study participants. 
Fibrinogen concentration  
Plasma fibrinogen levels were measured in DVT and PE subjects using an ELISA 
developed in our laboratory as previously described (Martinez et al., 2012, Heffron et al., 
2009). 
Clot formation and lysis time 
Thrombin (0.25 U/ml), CaCl2 (20 mM), and tissue plasminogen activator (tPA) (1.25 
μg/ml) (American Diagnostica, Stamford, CT) combined in TBS were simultaneously 
added to plasma (0.1 ml, final) from DVT and PE subjects. Changes in turbidity due to 
clotting and lysis were monitored spectrophotometrically at 350 nm for 6 hrs. Lag time 
was defined as the time for absorbance to change to .01 (OD) (Pieters et al., 2008). The 
rate of clot formation was measured as the slope of the linear part of the clot formation 
and lysis time curve during the transition from the zero absorbance to the maximum 
absorbance. Lysis time was defined as the time difference between the midpoint of the 
zero to maximum absorbance transition and the midpoint of the maximum to zero 
absorbance transition (Lisman et al., 2005). Clots with higher maximum absorbance are 
likely to take longer to lyse. To account for this as well as individual sample variance, 
 34 
lysis time was normalized form maximum absorbance (Collet et al., 2006). At a 
minimum each sample was measured in duplicate, and curves were averaged using 
OriginLab (Northampton, MA). 
Viscoelastic properties 
Viscoelastic properties were measured with a rheometer (AR-G2, TA Instruments, New 
Castle, DE) during plasma clot formation. Plasma clots were produced by the addition of 
thrombin (0.25 U/ml) (American Diagnostica, Stamford, CT) and CaCl2 (20 mM) 
combined in TBS (0.05 M Tris, 0.14 M NaCl pH 7.4) to plasma (0.1 ml, final) between 
the stainless steel stage of the rheometer base and a 40 mm parallel plate. To avoid 
drying, the outside of the forming clot was surrounded by mineral oil (3.52 mPa·s) 
(Cannon Instrument Company, State College, PA), which is immiscible with plasma. A 
time-sweep test was performed for 1 h under an oscillation procedure of 2 % strain at an 
angular frequency of 5 radians per second. All measurements were temperature 
controlled by a circulating water bath at 25 °C. The storage modulus and the loss 
modulus, measures of elastic and viscous properties respectively, were measured at 3 s 
intervals. At a minimum each sample was measured in duplicate, and curves were 
averaged using OriginLab. 
Factor XIIIa crosslinking 
Plasma in 10 µl aliquots was clotted with thrombin (0.25 U/ml) and CaCl2 (20 mM).  The 
reaction was quenched with lithium dodecyl sulfate sample buffer (4X, 25 µl) and 
immediately boiled at 100° C for 5 min. Samples were diluted 100 fold and run on a 
NuPAGE® 4-12 % Bis-Tris gel (Invitrogen, Carlsbad, CA), followed by western blot 
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analysis with a primary polyclonal rabbit anti-human fibrinogen antibody 
(Dakocytomation, Glostrup, Denmark) and secondary goat anti-rabbit IRDye680® 
conjugated IgG antibody (Rockland, Gilbertsville, PA). The blot was viewed and 
quantified using the Odyssey infrared imaging system (LI-COR, Lincoln, NE). γ-dimer 
and α-polymer formation were normalized as a percent of total γ and α chain, 
respectively, at each time point. 
Scanning electron microscopy 
As described above, thrombin (0.25 U/ml) and CaCl2 (20 mM) were added to plasma 
from DVT and PE subjects and allowed to clot for 2 hrs. Clots were then washed, fixed, 
dehydrated with serial ethanol dilutions followed by hexamethyldisilazane (Acros 
Organics, Fair Lawn, NJ), and sputter-coated with gold palladium as described previously 
(Weisel and Nagaswami., 1992). High definition micrographs were taken on a 
Philips/FEI XL20 scanning electron microscope (FEI, Hillsboro, Oregon).  Nine to 
twelve micrographs were taken for each sample. Fiber density and fiber bundling were 
quantified using Image J (Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland, USA, http://imagej.nih.gov/ij/, 1997-2011). For fiber density, 
micrographs were overlaid with a 6x6 rectangular grid, with each rectangle being 3x4 
µm
2
 in size. Values were normalized for the number of images taken and are reported as 
the mean number of fibers per 3x4 µm
2
 rectangle ± the standard error (SE). Fiber bundles 
and the number of fibers per bundle were counted for each image, resulting in a total area 
of 432 µm
2
. These values were normalized for number of images and are reported as the 
mean number of bundles or number of fibers per bundle ± SE.  
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Statistics 
All continuous variables were tested for Gaussian distribution by D’Agostino and 
Pearson omnibus normality test. For parametric distributions, an unpaired t-test was 
performed, and Welch’s correction was applied for unequal variances where required. 
Values are expressed as the mean ± SE. For nonparametric distributions, Mann Whitney 
U test was performed, and the median and the interquartile range (IQR) are reported. For 
comparisons between more than two groups, Kruskal Wallis one-way Anova test was 
used, followed by testing between groups with Dunn’s multiple comparison test. Values 
are expressed as mean ± SE. Correlations were assessed by Spearman rank correlation 
analysis. The presence of statistical outliers was determined by Grubb’s outlier test. A p-
value of 0.05 or less was considered statistically significant. All statistical calculations 
including linear regression analysis were generated and analyzed using GraphPad Prism 
(GraphPad Software, La Jolla, CA, USA). 
2.4 Results 
Study population characteristics 
A total of 291 subjects with suspected VTE were recruited for this study.  Only subjects 
positive for DVT or PE were included for experimental analysis. Of the 100 subjects with 
suspected DVT, 32 had a positive ultrasound and an additional 3 were determined to be 
positive on 90-day follow-up. Among the 191 subjects with suspected PE, 45 had a 
positive computed tomographic pulmonary angiography and 2 additional subjects were 
found to have new PE at 90 days. Patient demographics, disease history, risk factors, and 
medications are shown in Table 2-1. Significantly more DVT subjects were male 
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compared with PE. More DVT subjects had a previous history of peripheral artery 
disease, which is a reported risk factor for VTE (Sorensen et al., 2009, Eliasson et al., 
2006).  Immunosuppressant use, such as chemotherapeutics and glucocorticosteroids, was 
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increased in DVT subjects.  Other demographic variables, comorbidities, risk factors, and 
medication use were similar between DVT and PE subjects (Table 2-1). 
Plasma fibrinogen concentration 
Changes in fibrinogen concentration affect fibrin clot properties (Weisel and 
Nagaswami., 1992, Roberts et al., 1974). In addition, elevated fibrinogen levels are an 
accepted risk factor for arterial thrombosis, and may also play a role in VTE (Benderly et 
al., 1996, Folsom et al., 1997, van Hylckama Vlieg and Rosendaal., 2003). We measured 
fibrinogen concentration in the plasma of DVT and PE subjects by ELISA (Martinez et 
al., 2012, Heffron et al., 2009). Fibrinogen levels were similar between DVT and PE 
subjects (DVT: n=34, 5.20 ± 0.43 mg/ml; PE: n=38, 5.93 ± 0.54 mg/ml; p=NS), and did 
not differ between distal DVT, proximal DVT, or PE (Distal: n=9, 4.80 ± 0.60 mg/ml; 
Proximal: n=25, 5.35 ± 0.55 mg/ml; PE: n=38, 5.93 ± 0.54 mg/ml; p=NS). 
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Clot formation and lysis time 
Previously published data have shown that 
lysis time is faster in PE compared to DVT 
subjects (Undas et al., 2009). Clot 
formation and lysis time were measured in 
the plasma of DVT and PE subjects by 
spectrophotometry.  Lysis time was faster 
in PE subjects compared with DVT (Figure 
2-1; Table 2-2). The remaining variables of 
the clot formation and lysis time curves, 
lag time, rate of clot formation, and 
maximum absorbance, were similar for 
both DVT and PE subjects (Table 2-2).  
To further investigate if lysis time might 
contribute to embolization, DVT subjects were separated into distal and proximal DVT.  
One way Anova analysis showed that mean lysis times were different between the three 
groups (Figure 2-1; Table 2-2). Subsequent comparison between groups using Dunn’s 
multiple comparison tests shows that lysis time was significantly slower in distal DVT 
compared with PE.  No other clot formation and lysis time variables differed between 
distal DVT, proximal DVT, or PE. 
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Viscoelastic properties of fibrin clots 
A clot’s inherent viscoelastic properties may determine its ability to withstand shear 
forces within the venous lumen. Herein, the storage modulus and the loss modulus, which 
represents the elastic and viscous properties respectively, were measured throughout clot 
formation.  Averaged viscoelastic property curves for DVT and PE subjects are shown in 
Figure 2-2. Initial establishment of viscoelastic properties is accelerated in plasma fibrin 
clots of PE subjects compared with DVT. Evaluation of individual elastic property curves 
obtained from PE subjects show a decrease in the lag time (Figure 2-2; Table 2-3). In 
addition, linear regression analysis of averaged curves demonstrates an increase in the 
rate of elastic property formation in PE subjects compared with DVT (Figure 2-2; Table 
2-3). Similar results were obtained with viscous property curves. Despite differences in 
the initial phases of viscoelastic property formation, final elastic and viscous properties 
were similar between DVT and PE subjects.  
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Factor XIIIa crosslinking of fibrin  
We observed increased establishment of viscoelastic properties and faster lysis rates in 
clots derived from PE subjects compared to DVT. One possible explanation may be 
related to FXIIIa crosslinking of fibrin, which has been shown to increase both the 
storage and loss moduli (Ryan et al., 1999), as well as delay lysis time (Lorand and 
Jacobsen., 1962, Gormsen et al., 1967). To determine the contribution of FXIIIa 
 42 
crosslinking of fibrin to differences seen between DVT and PE subjects, the rate and 
extent of formation of γ-dimers and α-polymers were measured in the plasma of DVT 
(n=7) and PE (n=12) subjects over a 24 hr. period by western blot analysis. The 
formation of γ-dimers and α-polymers were normalized for total γ and α chain, 
respectively, at each time point. The rate and extent of γ-dimer formed was similar 
between DVT and PE subjects (Figure 2-3). Similar results were found for α-polymer 
(Figure 2-3). Correspondingly, loss of γ and α chains of fibrinogen as they became 
incorporated into γ-dimers and α-polymers, respectively, were similar between DVT and 
PE (data not shown). 
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Scanning electron microscopy to evaluate fibrin clot structure 
Alterations in fibrin clot structure, including changes in fiber density, diameter, bundling, 
and clustering have been associated with risk of thrombosis (Parastatidis et al., 2008, 
Collet et al., 2006, Machlus et al., 2011) and are related to lysis rates. Previous studies 
have shown that clots derived from PE subjects showed increased porosity compared to 
DVT (Undas et al., 2009). Fibrin clot structure was evaluated in 7 DVT and 8 PE subjects 
by scanning electron microscopy. Due to their relationship with porosity (Blomback et 
al., 1989), fiber density and fiber bundling were quantified from scanning electron 
micrographs using Image J (Figure 2-4). Histograms of fiber density display a Gaussian 
distribution and show that clots from DVT subjects have a mean of 34.36 ± 0.14 
fibers/area
2
, while PE fibrin clots have a mean of 31.38 ± 0.33 fibers/area
2
 (p<0.0001; 
Figure 2-4). Fiber density was not related to fibrinogen concentration, as Spearman rank 
correlation analysis showed no relationship between the two variables (r=0.0071; p=NS).  
Histograms of fiber bundling and the number of fibers per bundle were both asymmetric, 
and could therefore not be fit with Gaussian distributions (Figure 2-4). Comparison of 
means showed that neither fiber bundling (DVT: 3.73 ± 0.30 bundles/area
2
, n=7; PE: 3.36 
± 0.62 bundles/area
2
, n=8; p=NS) nor the number of fibers per bundle were significantly 
different between DVT and PE subjects (DVT: 4.25 ± 0.16 fibers/bundle, n=7; PE: 3.85 ± 
0.13 fibers/bundle, n=8; p=NS). Fiber bundling was also not related to fibrinogen 
concentration, as Spearman rank correlation analysis showed no relationship between the 
two variables (r=-0.1265; p=NS).  
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2.5 Discussion 
DVT and PE encompass two pathological states of one disease, VTE, and likely have 
contrasting risk factors and pathology that define each condition (van Langevelde et al., 
2012). Although much is known about the relationship between clot structure and arterial 
thrombosis, less is known about its role in VTE specifically concerning distinctions 
between DVT and PE. Furthermore, there is little information about embolization in 
general, despite the frequency of this condition and its clinical significance.  This study 
addresses differences in clot structure and functional properties in this population which 
might elucidate properties that are liable to lead to embolization. In this study, both the 
storage and loss moduli were established at an earlier time point and at a faster rate in PE 
subjects compared to DVT. Plasma fibrin clots from PE subjects also exhibited faster 
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lysis times than DVT subjects. FXIIIa crosslinking was similar between DVT and PE 
subjects and is thus unlikely to account for the differences in viscoelastic properties and 
lysis. We also observed that clots derived from PE subjects exhibit decreased fiber 
density compared to DVT. Together these findings suggest that the formation of fibrin 
fibers differs between DVT and PE, which are apparent in the final clot structures 
determined by scanning electron microscopy. Furthermore, accelerated establishment of 
viscoelastic properties occurs in the absence of any observable changes in the rate of clot 
formation or lag time by spectrophotometry. This is likely due to the increased sensitivity 
of rheometry to detect changes in clot formation compared with spectrophotometry. 
Clot formation and lysis are dynamic processes that occur simultaneously (Hoylaerts et 
al., 1982). During this process, tPA and plasminogen bind to fibrin, which acts as a 
cofactor in the conversion of plasminogen to plasmin (Hoylaerts et al., 1982). Larger 
fibrin structures are preferentially targeted compared to smaller ones, allowing for clot 
formation to proceed (Hoylaerts et al., 1982). During this process, tPA is limiting 
(Bannish et al., Acceptedb, Bannish et al., Accepteda), and clots with a decrease in the 
number of fibers being formed will have a higher tPA to fiber ratio. This may account, in 
part, for the accelerated rate of lysis in clots with decreased fiber density (Collet et al., 
2000), and may also suggest that in some cases, lysis begins at an earlier time point. The 
earlier establishment of viscoelastic properties in PE subjects specifies faster formation of 
fiber structures compared to DVT. It is possible that the earlier those structures are 
established in PE, the faster lysis can occur, creating instability and embolization prior to 
full clot formation. Evidence documenting the time course of initiation of thrombosis to 
embolization is lacking in humans, and to date, no animal models of PE from an 
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established venous thrombus exist. However, recent studies utilizing intravital 
microscopy to monitor real-time thrombus formation in a laser-induced injury model 
have shown that embolization can occur as the thrombus is forming, prior to full clot 
formation (Neyman et al., 2008, Stolla et al., 2011). This is one possible explanation for 
changes seen in the initial, but not the final phases of elastic property formation.  
However, if embolization occurs at a time point after the clot has fully formed it is not 
clear how differences in viscoelastic properties relate to the tendency to embolize.  
Among subjects presenting with acute DVT, identifying those at highest risk for PE could 
greatly inform treatment decisions. Although risk factors that characterize those subjects 
are lacking, evidence suggests that subjects with proximal vein thrombosis are at much 
higher risk of developing PE compared to subjects with distal vein thrombosis (Moser 
and LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994). In a sub-analysis of clot 
formation and lysis time properties, distal and proximal DVT subjects were compared for 
all clot formation and lysis time variables. Lysis time was significantly faster in PE 
compared to distal DVT, but not in proximal DVT. These data could indicate lysis time 
as a risk factor for PE. These conclusions must be viewed with caution however, due to 
small sample size. Additional studies with a larger population are necessary to confirm 
these findings. 
In this study we used SEM to visualize clot structure which revealed that fiber density 
was decreased in clots from PE subjects relative to DVT, and no differences were seen in 
fiber bundling. The decrease in fiber density is consistent with the finding that clot 
permeability in PE subjects is increased compared to DVT (Undas et al., 2009). Fiber 
density is related to several factors including fibrinogen and thrombin concentration, 
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fibrinogen variants, post translational modifications of fibrinogen, and other plasma 
constituents (Weisel and Nagaswami., 1992, Parastatidis et al., 2008, Konings et al., 
2011, Herbert et al., 1998, Dang et al., 1989, Langer et al., 1988). Fibrinogen 
concentration cannot be the source of changes in fiber density as it was comparable 
between DVT and PE subjects, similar to what has been shown in related studies (Undas 
et al., 2009). Additional studies are necessary to determine the causative factors that 
produce differences in fibrin clot structure, lysis, and viscoelastic properties between 
DVT and PE subjects. 
In summary, compared with DVT, PE subjects exhibit faster lysis times, possibly due to 
lower fiber density, as well as an enhanced establishment of clot viscoelastic properties.  
These properties distinguish PE subjects from DVT and may define structural 
characteristics that delineate pathologies within VTE and predispose subjects to 
embolization.  
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3.1 Abstract 
The pathogenesis of venous thromboembolism (VTE) is linked to inflammation and 
oxidant production, although specific markers for these pathways with pathological 
relevance to VTE have not been explored. The coagulant protein fibrinogen is post-
translationally modified by nitric oxide-derived oxidants to nitrated fibrinogen in both 
acute and chronic inflammatory states. Therefore, nitrated fibrinogen may serve as a 
marker of inflammation and oxidative stress in VTE. To test this hypothesis we enrolled 
subjects (n=251) presenting with suspected VTE at the Hospital of the University of 
Pennsylvania emergency department, 50 (19.9 %) of whom were positive by imaging or 
90-day follow-up. Mean nitrated fibrinogen was elevated in VTE positive (62.7 nM, 95 
% CI 56.6-68.8) compared to VTE negative subjects (54.2 nM, 95 % CI 51.4-57.1; p < 
0.01). Subjects in the highest quartile of nitrated fibrinogen had an increased risk of VTE 
compared with subjects in the lowest quartile (OR 3.30; 95 % CI 1.25-8.68; p<0.05). This 
risk persisted after univariate adjustment for age, active cancer, and recent surgery, but 
not after multivariate adjustment. Mean fibrinogen levels measured either by the Clauss 
assay or by ELISA were not different between VTE negative and positive subjects. These 
data indicate that nitrated fibrinogen is an oxidative risk marker in VTE, providing a 
novel mechanistic link between oxidant production, inflammation, and VTE. 
 
 
 
 
 50 
3.2 Introduction 
Venous thromboembolism (VTE) is a common thrombotic disease that encompasses both 
deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE affects around 1 per 
1000 people per year within the United States, with increasing incidence for congenital 
and acquired thrombophilic risk factors (Anderson et al., 1991, Salomon et al., 1999, 
Pabinger et al., 1992). VTE is a chronic disease with 30 % of patients experiencing a 
recurrent event over 10 years (Heit et al., 2000a, Schulman et al., 2006), and is estimated 
to account for between 100,000 and 180,000 deaths each year (Rathbun., 2009). Thus, 
VTE represents a significant health problem that requires considerable attention. 
The precise molecular and biochemical mechanisms of thrombus initiation in VTE 
remain unclear. Virchow proposed that changes in blood rheology, induction of a 
hypercoagulable state, or endothelial injury are conditions required for venous 
thrombosis (Virchow., 1856). More recent studies indicate that inflammation plays an 
important role in VTE. However, the interplay between inflammation and Virchow’s 
triad is still unresolved. One possibility is that components of the triad activate or damage 
endothelial cells within the vein wall resulting in upregulation of receptors for 
inflammatory and pro-coagulant molecules. Electron micrographs of early thrombus 
formation show leukocyte adhesion to the vein wall (Schaub et al., 1984), presumably 
through the binding of P- and E-selectins that are expressed on activated endothelial cells 
(Myers et al., 2002, Geng et al., 1990). Leukocytes shed tissue factor-bearing 
microparticles, which induce coagulation and the production of a fibrin clot 
(Hrachovinova et al., 2003). Neutrophils and monocytes, two of the most prevalent 
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leukocytes in venous thrombi, are also able to generate nitrating intermediates, capable of 
lipid peroxidation and nitration of proteins (Brennan et al., 2002, Hazen et al., 1999).   
One protein known to be modified by tyrosine nitration is the coagulant protein 
fibrinogen. Upon activation of the coagulation cascade, circulating plasma fibrinogen is 
cleaved by thrombin to fibrin monomers, which polymerize to form a fibrin clot.  Recent 
studies demonstrate an emerging role for nitrated fibrinogen that links inflammation and 
oxidant production to coagulation. Nitrated fibrinogen is elevated in the plasma of 
subjects with coronary artery disease (CAD) and in smokers (Vadseth et al., 2004, 
Parastatidis et al., 2007). Additionally, in humans injected with small amounts of 
lipopolysaccharide, plasma levels of nitrated fibrinogen increase and remain elevated for 
at least 72 hrs. post-injection (Heffron et al., 2009). This increase follows an elevation of 
circulating myeloperoxidase, an enzyme localized to the azurophilic granules of 
neutrophils, which is released during neutrophil activation and is capable of generating 
nitrating intermediates (Brennan et al., 2002). Although these data suggest that nitrated 
fibrinogen plays a key role linking inflammation, oxidant production, and arterial 
thrombotic diseases, its role in VTE remains undefined.  
Moreover, nitrated fibrinogen is not simply a marker of inflammation and oxidative 
stress, but also has functional effects on fibrinogen and fibrin clotting.  Fibrinogen 
nitration was shown to increase the rate of fibrin clot formation, diminish clot lysis rate, 
and alter fibrin clot structure and viscoelastic properties (Vadseth et al., 2004, Heffron et 
al., 2009, Parastatidis et al., 2007). These functional effects suggest that nitrated 
fibrinogen may represent a risk factor for increased thrombotic tendency during 
inflammation and oxidant stress. However, the levels of nitrated fibrinogen in VTE have 
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not been ascertained. Herein we quantified the levels of nitrated fibrinogen in subjects 
presenting to the emergency department with suspected VTE and evaluated if nitrated 
fibrinogen is a biochemical risk factor that could explain associations of oxidative stress 
and inflammation with thrombotic complications in VTE. 
3.3 Materials and Methods 
Study population 
We performed a prospective cohort study from January 2010 to March 2011 of 
consecutive subjects 18 years of age or older presenting to the Hospital of the University 
of Pennsylvania emergency department with suspected acute lower extremity DVT or PE.  
Exclusion criteria included history of VTE within the prior 4 weeks, unavailable for 90 
day follow-up, and inability to provide informed consent. DVT was diagnosed by 
compression ultrasonography and PE by computed tomographic pulmonary angiography.  
Subjects with negative imaging were contacted by telephone 90 days after enrollment to 
confirm that they did not develop clinically apparent VTE. Those who reported 
development of VTE over this interval despite negative imaging were also considered 
positive for DVT and/or PE. Secondary variables were also collected including, 
demographic information, thrombotic risk factors, comorbidities, and medications. Prior 
to initiation of anticoagulant therapy in the emergency department, blood was collected 
from subjects in 3.2 % sodium citrate (BD Vacutainer, Franklin Lakes, NJ). Blood was 
centrifuged at 150 g for 15 min, and the supernatant, platelet rich plasma, was transferred 
to a new tube. Platelet rich plasma was then centrifuged at 10,000 g for 10 min to obtain 
platelet poor plasma, followed by storage at -80° C for future analysis. Study design was 
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approved by the Institutional Review Board Involving Human Subjects at the University 
of Pennsylvania and written informed consent was obtained from all study participants. 
Plasma nitrated fibrinogen levels 
Nitrated fibrinogen levels were measured in plasma using an ELISA described previously 
(Heffron et al., 2009). Briefly, 96-well plates were coated with 10 µg/ml anti-
nitrotyrosine antibodies generated and described elsewhere (Heijnen et al., 2006) in 50 
mM carbonate buffer pH 9, and incubated at 4 °C under constant rocking overnight. The 
next day, plates were washed with 50 mM Tris, 150 mM NaCl, 0.05 % Tween-20 (TBS-
T). Plates were blocked with 3 % bovine serum albumin (BSA) (Roche Diagnostics, 
Mannheim, Germany) (wt/vol) in TBS-T for 2 h at 37° C, followed by incubation with 1 
% BSA in TBS-T for 1 h at 37° C. A standard curve was created from purified fibrinogen 
(American Diagnostica, Stamford, CT) that had been chemically nitrated and the levels of 
nitration were independently determined (Heffron et al., 2009). Plasma samples were 
diluted (1:10, 1:20) in 1 % BSA in TBS-T, added to the plate in duplicate and incubated 2 
h at room temperature under constant rocking. Plates were washed with TBS-T and 
coated with 0.3 µg/ml HRP-conjugated rabbit-anti-human fibrinogen polyclonal antibody 
(DakoCytomation, Glostrup, Denmark) in 1 % BSA in TBS-T. After 2 h incubation at 
room temperature under gentle rocking, the plates were washed with TBS-T and 
developed with TMB substrate (KPL, Gaithersburg, MD) followed by quenching of the 
reaction with 2 M sulfuric acid (Fisher Scientific, Fair Lawn, NJ). The absorbance was 
measured at 405 nm (Molecular devices, Sunnyvale, CA). Nitrated fibrinogen values 
were normalized to quality control plasma run with each plate. Each subject sample was 
analyzed a minimum of three times and samples that exceeded 15 % coefficient of 
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variation were excluded from analysis. The normalized mean intra-assay and inter-assay 
variations were 8.23 % and 9.32 %.  
Plasma fibrinogen level 
Fibrinogen levels were measured in plasma using an ELISA previously described 
(Heffron et al., 2009). Ninety-six well plates (Maxisorb, Nunc, Rochester, NY) were 
coated with 10 µg/ml mouse anti-fibrinogen monoclonal antibody (Heffron et al., 2009) 
in carbonate buffer pH 9, and incubated at 4° C, rocking overnight. The next day, plates 
were washed with TBS-T and blocked with 3 % BSA in TBS-T for 2 h at 37° C. A 
standard curve was created from purified fibrinogen (American Diagnostica, Stamford, 
CT) in TBS-T. Plasma was diluted (1:5000, 1:10000), added to the plate in triplicate, and 
incubated for 1 h 37° C. Plates were washed with TBS-T, then coated with 0.3 µg/ml 
HRP-conjugated rabbit-anti-human fibrinogen polyclonal antibody (DakoCytomation, 
Glostrup, Denmark) in 1% BSA in TBS-T and incubated 1 h at room temperature. The 
plate was developed with the TMB peroxidase substrate as described above. Fibrinogen 
values were normalized to quality control plasma run with each plate. The normalized 
mean intra-assay and inter-assay variations were 11.23% and 14.0%.   
Plasma fibrinogen levels were measured by Clauss method (Clauss., 1957) using a 
Destiny Max coagulation analyzer according to manufacturer’s protocol (Trinity Biotech, 
Co. Wicklow, Ireland).   
D-dimer 
Plasma D-dimer levels were measured at the Hospital of the University of Pennsylvania 
coagulation laboratory using the Vidas ® D-dimer exclusion assay™ (bioMérieux, Lyon, 
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France). This assay measures the fibrin degradation product (FDP) D-dimer by an 
enzyme linked fluorescence assay. This sandwich ELISA based method uses two anti-
FDP monoclonal antibodies (P10B5E12C9 and P2C5A10) coupled with fluorescence 
detection (de Moerloose et al., 1996, Perrier et al., 1999). In accordance with the 
manufacturer’s instructions, a D-dimer level <0.5 μg/ml was considered negative. 
The laboratory personnel and technologists performing all assays were blinded to subject 
outcome. Laboratory results obtained on the archived plasma samples were not made 
available to clinicians or subjects.  
Statistics 
Gaussian distribution was tested for all continuous variables using D'Agostino & Pearson 
omnibus normality test, which indicated non-parametric distributions for all variables 
within our data. Thus, comparisons between groups were made using Mann-Whitney U 
test. Nitrated fibrinogen, D-dimer, and fibrinogen are given as the mean and the 95 % 
confidence interval (CI). The adjusted model for nitrated fibrinogen levels was created 
using the generalized linear model, which accounted for demographics, comorbidities, 
and VTE risk factors. Odds ratios (OR) were compared by Fishers exact test. Trends in 
nitrated fibrinogen levels by quartile were compared by Chi-squared analysis. A p-value 
<0.05 was considered statistically significant.  All statistical calculations were generated 
and analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA), or R-Statistical 
package (http://www.r-project.org/). 
 56 
 
 
 
 
 57 
3.4 Results 
Subject characteristics 
A total of 251 subjects were enrolled in this study.  Of the 83 subjects with suspected 
DVT, 18 had a positive ultrasound and an additional 3 were determined to be positive on 
90-day follow-up. Among the 168 subjects with suspected PE, 28 had a positive 
computed tomographic pulmonary angiography and 1 additional subject was found to 
have new PE at 90 days. Subject demographics, disease history, risk factors, and 
medications are shown in Table 3-1. Three well-accepted risk factors for VTE were more 
prevalent in the VTE positive subset: advanced age, active cancer, and surgery within the 
past 6 weeks. VTE positive subjects were significantly older compared with negative 
subjects and were more likely to have active cancer or recent surgery. Thrombophilia 
testing was not performed as part of the study. Nevertheless, three subjects reported a 
history of hereditary thrombophilia including one with protein C and two with protein S 
deficiency. Additionally, two subjects reported having antiphospholipid syndrome. No 
other measured demographic variables, comorbidities, risk factors, or medication use 
differed between VTE positive and negative subjects (Table 3-1).  
Fibrinogen levels in VTE subjects 
Fibrinogen levels were quantified by ELISA, which measures fibrinogen antigen, and the 
Clauss assay, which measures fibrin clotting time. The mean levels of fibrinogen 
compared by Mann Whitney U test were not different between subjects with and without 
VTE by either Clauss assay or by ELISA (Figure 3-1). Fibrinogen levels were also 
similar between DVT and PE subjects irrespective of the assay employed (Clauss: DVT: 
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3.8 mg/ml, 95 % CI 3.0-4.6, n=17; PE: 4.5 mg/ml, 95 % CI 3.6-5.4, n=27; ELISA: DVT: 
5.5 mg/ml, 95 % CI 4.4-6.5, n=21; PE: 5.6 mg/ml, 95 % CI 4.7-6.5, n=28). ELISA-
determined fibrinogen levels were higher than those reported by Clauss assay, which is 
consistent with findings in previous studies (Kallner et al., 2003).  
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Nitrated fibrinogen levels in VTE subjects 
Nitrated fibrinogen was measured by an ELISA as described previously (Heffron et al., 
2009). The levels of nitrated fibrinogen were interpolated from a standard curve created 
with purified fibrinogen that was chemically nitrated and levels of nitration were 
independently determined (Heffron et al., 2009). To ensure the integrity of each assay, 
every 96-well plate included a quality control plasma standard, and intra- and inter-assay 
variation did not exceed 15 %. The mean levels of nitrated fibrinogen were significantly 
higher in VTE positive compared to VTE negative subjects (Figure 3-1). Nitrated 
fibrinogen levels were not different between DVT and PE subjects (DVT: 60.9 nM, 95 % 
CI 52.3-69.6, n=17; PE: 63.9 nM, 95 % CI 55.2-72.5, n=27). 
Previous data indicated that one functional effect of fibrinogen tyrosine nitration was 
increased rate of fibrin formation. Since the Clauss assay relies on fibrin clotting time in 
plasma to assess fibrinogen levels, Spearman correlation analysis was used to evaluate 
the relationship between nitrated fibrinogen and fibrinogen levels (Figure 3-1). Nitrated 
fibrinogen correlated linearly with Clauss measured fibrinogen levels (r=0.31, 95 % CI 
0.18-0.40, n=207; p<0.0001).   
D-dimer levels in VTE subjects 
D-dimers are fibrin degradation products that are produced in response to clot lysis by 
plasmin, and are used as a diagnostic marker for VTE (de Moerloose et al., 1996, 
Bounameaux et al., 1991, Di Nisio et al., 2007, Bozic et al., 2002, Declerck et al., 1987).  
D-dimer was measured with the Vidas ® D-dimer exclusion assay™ according to 
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manufacturer’s instructions. As expected, mean D-dimer levels were significantly higher 
in VTE positive versus VTE negative subjects (Figure 3-1).   
Odds ratio for venous thromboembolism across increasing nitrated fibrinogen levels 
Cubic spline curves with 95 % CI 
(n=226) were constructed to illustrate 
the relationship between nitrated 
fibrinogen levels and odds ratio of 
clinically documented VTE (Figure 
3-2). This analysis shows a strong 
association between nitrated 
fibrinogen levels and increased risk 
for VTE (p<0.005). A similar 
relationship was found for rates of 
VTE across increasing nitrated fibrinogen quartiles (χ
2
 for trend 7.69; p<0.01) (Table 3-
2). Subjects in the highest quartile were compared with those in the lowest quartile and 
were found to have an increased risk of VTE. This risk was maintained after univariate 
adjustment for the risk factors found to be elevated in our VTE positive subject 
population: advanced age, active cancer, and recent surgery (Table 3-2, models 1, 2, and 
3). However, multivariate analysis with these risk factors did not reach statistical 
significance (Table 3-2, model 4). This may reflect the small size of our VTE positive 
subject population, where additional adjustments reduce the final sample size and 
eliminate statistical significance. 
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3.5 Discussion 
Previous studies have implied that inflammation and oxidative processes may be 
mechanistically linked to the pathogenesis of VTE (Wakefield et al., 1995, Nordenholz et 
al., 2008, Parastatidis et al., 2008, Brennan et al., 2002, Vadseth et al., 2004, Heffron et 
al., 2009, Hazen et al., 1999, Henke et al., 2004, Lo et al., 1995, Eiserich et al., 1998, 
Pignatelli et al., 2001). Nitration of proteins and specifically, nitrated fibrinogen has been 
quantified in the plasma of subjects that experience inflammatory changes and oxidative 
burden (Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 2009). In this study 
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the data indicate that oxidants, specifically nitrating intermediates produced in response 
to inflammation in VTE, result in nitration of fibrinogen. The levels of nitrated fibrinogen 
were significantly elevated in subjects with acute VTE compared to those found to be 
negative for the disease. This increase was not dependent on changes in fibrinogen, as 
mean levels of fibrinogen were similar between the two groups. Based on previous 
studies, the levels of nitrated fibrinogen in VTE negative subjects are higher than would 
be expected in healthy non-smoking controls (Parastatidis et al., 2008, Vadseth et al., 
2004). This is likely due to the presence of inflammatory and oxidative conditions in the 
VTE negative population, including CAD and smoking that are associated with increased 
plasma concentration of nitrated fibrinogen (Parastatidis et al., 2008, Vadseth et al., 2004, 
Heffron et al., 2009). Elevated levels of nitrated fibrinogen in VTE, CAD, and smokers 
suggest that inflammation and the production of nitric oxide-derived oxidants are present 
in thrombotic disorders as well as in those at risk for the disease. Previous research on the 
functional effects of nitration on fibrinogen indicates that this modification contributes to 
a prothrombotic phenotype (Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 
2009). Thus, nitrated fibrinogen may serve as a comprehensive marker for activation of 
inflammatory pathways during thrombosis. Increasing nitrated fibrinogen levels were 
positively associated with risk of VTE. When compared with subjects in the lowest 
quartile of nitrated fibrinogen, those in the highest quartile had a significantly increased 
risk of VTE. This relationship persisted after adjusting individually for the risk factors 
that were elevated in the VTE positive group: advanced age, active cancer, and recent 
surgery. However, this risk was not maintained after adjusting for the combined factors.  
The relatively small VTE positive subject group may account for this difference, whereby 
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adjustment reduces the positive group sample size and eliminates statistical significance. 
A larger study would be needed to address this. The loss of significance in our 
multivariate regression analysis may also suggest that subjects with more than one of 
these risk factors also have elevated nitrated fibrinogen levels independent of VTE. 
Earlier work has shown that nitrated proteins, including nitrated fibrinogen were 
significantly elevated in lung cancer subjects (Pignatelli et al., 2001). Further studies 
investigating nitrated fibrinogen in advanced age, various cancer types, and surgical 
patients would be necessary to evaluate these effects. Advanced age, malignancy, and the 
postoperative state are well-accepted risk factors for VTE (Anderson et al., 1991, Heit et 
al., 2000b) and were more prevalent among VTE positive than negative subjects in our 
study. Other established risk factors were present in similar proportions among the two 
groups, possibly owing to the relatively small size of our study and the small number of 
subjects harboring such risk factors.   
In this study, nitrated fibrinogen was found to be elevated in the setting of acute VTE. It 
remains to be determined whether this elevation reflects an underlying mediator of VTE 
pathology or is merely a transient epiphenomenon of acute thrombosis. Studies in which 
nitrated fibrinogen levels are measured in those at risk for VTE, as well as in the weeks 
and months following an event are needed to address this question, and may provide 
valuable information regarding VTE recurrence.  
Previous work has revealed that fibrinogen is targeted for oxidative modifications in vivo 
(Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 2009, Parastatidis et al., 
2007, Pignatelli et al., 2001). Tyrosine nitration even in the presence of other oxidized 
amino acids was shown to significantly accelerate clot formation and factor XIII cross-
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linking (Vadseth et al., 2004). Incorporation of nitrated fibrinogen molecules into fibrin 
clots was documented by immune-electron microscopy and was found to alter clot 
architecture in a dose-dependent manner (Parastatidis et al., 2008, Vadseth et al., 2004). 
Changes in structure were accompanied by changes in viscoelastic properties and a 
decrease in dissolution by the fibrinolytic systems (Parastatidis et al., 2008, Vadseth et 
al., 2004). Removal of the nitrated fibrinogen molecules restored the kinetics of fibrin 
clot formation and architecture (Parastatidis et al., 2008). These profound effects on 
fibrin clot structure were produced by a relative small fraction of fibrinogen molecules 
modified by nitration. Based on previous data and data reported herein, the yield of 
nitration represents 1-6 % of fibrinogen molecules (Parastatidis et al., 2008). Kinetic 
analysis of fibrin formation revealed that insertion of nitrated fibrinogen molecules 
accelerated lateral aggregation, an event that follows the initial nucleation and the 
formation of half-staggered, double stranded protofibrils (Doolittle and Pandi., 2006, 
Geer et al., 2007, Litvinov et al., 2007). This acceleration is likely due to increased B-
knob:b-hole interactions, which are facilitated by the site specific nitration of two 
tyrosine residues near the b-hole of the β chain (Parastatidis et al., 2008). Overall, the 
concept that 1 nitrated molecule per 100 normal fibrinogen molecules can initiate the 
catalytic increase in lateral aggregation is intriguing and consistent with observations 
from other proteins that require nucleation events to form protein fibers (Hodara et al., 
2004). These previous studies suggest that the elevated levels of nitrated fibrinogen in 
VTE positive subjects would result in an increase in the kinetics of clot formation and 
subsequent changes in clot architecture. Additional studies are necessary to address this 
hypothesis.  
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In addition to nitrated fibrinogen, D-dimer levels were significantly elevated in VTE 
positive subjects consistent with previous studies (de Moerloose et al., 1996, 
Bounameaux et al., 1991, Di Nisio et al., 2007, Bozic et al., 2002, Declerck et al., 1987).  
Sensitivity and specificity for D-dimer at 0.5 µg/ml cutoff in this subject population were 
100 % (95 % CI 91.6-100) and 22.3 % (95 % CI 16.1-29.6), respectively and are similar 
to what has been previously reported for the Vidas ® D-dimer exclusion assay™ (de 
Moerloose et al., 1996, Di Nisio et al., 2007, Freyburger et al., 1998). 
Fibrinogen is an independent risk factor and predictor of CAD and associated morbidity 
and mortality (Benderly et al., 1996, Folsom et al., 1997). However, its role in VTE 
remains unclear. The Leiden Thrombophilia Study (LETS) showed elevated fibrinogen 
levels measured by Clauss assay in DVT subjects compared with healthy controls (Koster 
et al., 1994). However, in later investigations within LETS, increased risk of DVT with 
increasing fibrinogen levels was only found in subjects >45 yrs. In subjects <45 yrs., 
fibrinogen levels in the 95
th
 percentile did not confer increased risk of DVT (van 
Hylckama Vlieg and Rosendaal., 2003). Furthermore, in two separate studies in subjects 
with suspected PE, the levels of fibrinogen were significantly lower in subjects diagnosed 
as positive versus negative for the disease (Kucher et al., 2003b, Kucher et al., 2003a). In 
this study, fibrinogen levels were similar between VTE positive and negative groups, and 
there were no differences in DVT versus PE subjects. Subject population or sample size 
may account for the differences between this study and LETS, where DVT subjects were 
compared to a large number of healthy age and sex-matched controls. Likewise, subject 
population may also explain the dissimilarity between this study and the two previous 
studies investigating fibrinogen in PE (Kucher et al., 2003b, Kucher et al., 2003a). 
 66 
Overall, fibrinogen nitration in the VTE subjects certainly reflects active inflammatory 
and oxidative states that could favor a pro-coagulant environment resulting in fibrin 
structures with altered biochemical and biophysical properties and structure. These 
alterations in fibrin clots may profoundly impact the pathology of VTE.   
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CHAPTER 4 
Summary and Discussion 
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4.1 Fibrin clot properties and structure are differentially altered in VTE subjects 
Deep vein thrombosis (DVT) and pulmonary embolism (PE) share a common etiology, 
but have divergent outcomes. Thus, it is likely that there are coinciding, as well as 
distinct characteristics that define each condition (van Langevelde et al., 2012). Previous 
studies have shown that alterations in clot structure produce changes in the functional 
properties of clots including clot formation, lysis, and viscoelastic properties. 
Furthermore, these clot characteristics were also related to risk for arterial thrombosis and 
venous thromboembolism (VTE) (Parastatidis et al., 2008, Collet et al., 2006, Undas et 
al., 2009). While the cause of embolization remains unknown, it is likely related to the 
ability of the clot to withstand the shear forces within the vessel. Thus, alterations in clot 
structure may differentiate patients that embolize from those that do not. This is the first 
study to evaluate clot structure and functional properties in DVT and PE subjects. 
Compared to subjects with isolated DVT, clots formed from PE subjects exhibited 
enhanced establishment of viscoelastic properties as evidenced by a decrease in the lag 
time and an increase in the rate of both elastic and viscous property formation. In 
spectrophotometry assays, clots formed from PE subjects showed a faster lysis time, but 
did not differ in lag time, rate of clot formation, or maximum absorbance. Activated 
factor XIII (FXIIIa) crosslinking was also similar between the two groups. Fibrin fiber 
density was decreased in PE subjects, although fiber bundling remained unaffected.  
4.1.1 Fibrinolysis may regulate embolization 
Impaired fibrinolysis has been associated with both arterial and venous thrombotic 
diseases (Parastatidis et al., 2008, Collet et al., 2006, Undas et al., 2009, Machlus et al., 
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2011). Inability of the body’s own internal mechanisms to clear thrombi can result in 
occlusion of vessels and lead to outcomes such as DVT, PE, and myocardial infarction. 
This is the proposed mechanism by which elevated levels of circulating fibrinogen 
become a risk factor for arterial thrombotic diseases (Machlus et al., 2011). However, the 
paradigm appears to take a different course concerning embolic subjects. We observed 
faster lysis times in PE subjects compared to DVT. Concomitantly, lysis time was faster 
in PE compared to distal DVT, but not proximal DVT, where patients are disposed to 
embolization (Moser and LeMoine., 1981, Kakkar et al., 1969, Moser et al., 1994). 
Although clot formation and lysis time were not evaluated in a non-VTE population in 
this study, previous studies have observed slower lysis rates in both DVT and PE subjects 
compared with healthy controls (Undas et al., 2009). Together, these previous studies and 
ours suggest that 1) slower lysis alone is a risk factor for thrombosis and 2) changes in 
propensity for lysis may predispose a clot towards embolization. These changes may be 
due to differences in shear stress, alterations in venous endothelium, or alterations in clot 
structure due to local inflammatory or coagulant mediators.  
Fibrin clot structure is the most important determinant of lysis rates. Clots composed of 
thinner fibers that are more densely packed or heterogeneous clot structures with bundles 
or clusters tend to lyse at a slower rate (Collet et al., 2000, Parastatidis et al., 2008). The 
converse is also true, where thick fibers that are less densely packed lyse more quickly 
(Collet et al., 2000). This is due to the lateral transection of plasmin across fibers as 
opposed to lysis from the outside in of individual fibers (Collet et al., 2000). PE subjects 
exhibited decreased fiber density compared to DVT, which may account for the faster 
lysis observed.   
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4.1.2 Clots formed from PE subjects establish viscoelastic properties faster than 
DVT 
Previous studies evaluating the role of viscoelastic properties in arterial thrombotic 
diseases have observed changes in final viscoelastic properties (Collet et al., 2006). 
Specifically, clots from premature coronary artery disease subjects have increased elastic 
properties i.e. stiffer final clot structure.  In this study, clots from PE subjects exhibited 
increased rate of the establishment of both the elastic and viscous properties, with no 
differences in final viscoelastic properties. To date, no studies have evaluated clot 
viscoelastic properties in VTE compared to controls, or between DVT and PE subjects. 
Thus, these findings may represent unique clot functional properties involved in 
embolization.  
Viscoelastic properties are influenced by clot structure. In this study, clots from PE 
subjects had decreased fiber density with no differences in bundling and no apparent 
cluster formation. Previous studies have shown that clots composed of thinner fibers with 
increased fiber density have increased elastic properties (Collet et al., 2006, Roberts et 
al., 1974). Heterogeneous clot structures composed of fiber clusters or bundles also tend 
to have a higher elastic component (Parastatidis et al., 2008, Bale et al., 1985). Earlier 
establishment of viscoelastic properties in PE subjects suggests that there are distinctions 
in the fibers formed during clot formation, which is evident by differences in fiber 
density by SEM. However, the relationship between viscoelastic properties and clot 
structure is complicated by other mediators such as coagulation factors, fibrinogen 
variants and post-translational modifications, and will be discussed further below. 
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Additional studies will be necessary to address if and how these mediators affect 
viscoelastic properties and clot structure in DVT and PE subjects.  
Clot formation and lysis are processes of coagulation that occur simultaneously. 
Together, tissue plasminogen activator (tPA) and plasminogen bind to fibrin forming a 
ternary complex (Hoylaerts et al., 1982). Here fibrin acts a cofactor for the conversion of 
plasminogen to plasmin. In addition, tPA and plasminogen preferentially target larger 
fibrin structures, which allow coagulation to proceed. The faster rate of establishment of 
viscoelastic properties in PE subjects may allow tPA and plasmin to bind and begin lysis 
at an earlier time point. This process would likely lead to incomplete or unstable 
structures and possibly embolization. Evidence for a mechanism of embolization is 
lacking, but studies using intravital microscopy evaluating models of both arterial and 
venous thrombosis with nitrogen laser injury have observed embolization as a byproduct 
of thrombosis, occurring during thrombus formation rather than after the thrombus has 
been established (Neyman et al., 2008, Stolla et al., 2011). This might be one way in 
which changes in the initial phases of viscoelastic property formation contribute to 
embolization.  However, if embolization occurs at a time point after the clot has fully 
formed it is not clear how these differences relate to the tendency to embolize.  
4.1.3 FXIIIa crosslinking of fibrin does not contribute to differences in fibrin clot 
properties 
FXIII is a transglutaminase activated by thrombin cleavage of its N-terminal activation 
peptide, resulting in FXIIIa crosslinking of fibrin γ and α chains to create γ-dimers and α-
polymers, respectively (Nakamura et al., 1975). The main function of FXIIIa crosslinking 
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is to provide stability and prevent degradation of the fibrin clot. Clots that are not 
crosslinked by FXIIIa are lysed at a faster rate (Lorand and Jacobsen., 1962, Gormsen et 
al., 1967). The rate and extent of FXIIIa crosslinking of α and γ chains of fibrin in clots 
within our DVT and PE population were evaluated, and no differences were found 
between the two groups. Thus, the faster lysis rate observed in clots formed from PE 
subjects cannot be attributed to FXIIIa crosslinking of fibrin. However, FXIIIa also 
crosslinks α2-antiplasmin (α2-PI) to fibrin, which also delays lysis time (Lorand and 
Jacobsen., 1962, Gormsen et al., 1967). Further studies are required to determine if α2-PI 
is crosslinked to fibrin in DVT and PE subjects and how this effects lysis time.  
FXIII also provides the clot with a large extensibility, and in its absence, protofibrils slide 
past one another (Gerth et al., 1974, Brown et al., 2009). Overall, FXIIIa crosslinking 
enhances the elastic properties of clots (Gerth et al., 1974, Nelb et al., 1976), which may 
have functional consequences on the ability of the clot to withstand shear forces of blood 
flow within the vessel. Because FXIIIa crosslinking was similar between DVT and PE 
subjects, it is unlikely that the differences in viscoelastic properties are attributed to 
FXIIIa crosslinking of fibrin.  
4.1.4 Fibrinogen variants, fibrinogen post-translational modifications, and plasma 
constituents may contribute to differences between DVT and PE 
Although differences in viscoelastic properties, lysis time, and fiber density were 
observed between DVT and PE subjects, the cause of these alterations remains unknown. 
Fibrinogen concentration, variants, and post-translational modifications, and other plasma 
constituents have been shown to affect fibrin clot formation and structure. One of the 
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main effectors of fibrin clot structure is fibrinogen concentration. Increased fibrinogen 
levels result in faster clot formation, slower lysis, an increased elastic property, and a 
dense fibrin meshwork composed of thinner fibers (Weisel and Nagaswami., 1992, Collet 
et al., 2006, Machlus et al., 2011). Elevated fibrinogen levels are considered as a risk 
factor for arterial thrombosis (Machlus et al., 2011, Benderly et al., 1996, Folsom et al., 
1997), however fibrinogen levels and risk of VTE remain unclear. We and others did not 
observe differences in plasma fibrinogen levels between VTE negative and positive 
subjects (Martinez et al., 2012, van Hylckama Vlieg and Rosendaal., 2003), or between 
DVT and PE. Thus, plasma fibrinogen levels are unlikely to account for the differences 
observed between DVT and PE subjects. 
 A naturally occurring splice variant of the γ chain is γ’, which contains an additional 20 
amino acids in place of the last 4 (Wolfenstein-Todel and Mosesson., 1981). About 10 % 
of fibrinogen molecules contain γ/γ’ heterodimers, while < 1 % contain γ’/γ’ homodimers 
(Mosesson et al., 1972). Clots formed from γ’/γ’ have thinner fibers, smaller pores, more 
bundling and free fiber ends (Gersh et al., 2009).The additional 20 amino acids are 
negatively charged and contain two tyrosine sulfation sites that increase thrombin binding 
affinity, and may account for the antithrombin activity of fibrin (Meh et al., 2001). 
Studies have shown that subjects with lower γ’ levels are at increased risk of DVT (Uitte 
de Willige et al., 2005). To date, no studies have evaluated γ’ levels in DVT and PE, but 
the ratio of plasma γ’/γ fibrinogen may affect clot structure and thus, the propensity for 
embolization.  
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Fibrinogen is modified by various post-translational modifications including sulfation 
(above), homocysteinylation, tyrosine nitration, and oxidation (Vadseth et al., 2004, 
Collet et al., 2004, Sauls et al., 2006, Shimizu et al., 1986). Homocysteine (Hcy) is a 
sulfur containing amino acid that is involved in the metabolic cycle of methionine. 
Homocysteinylation occurs through addition of the Hcy cyclic thioester, Hcy thiolactone 
to fibrinogen (Sauls et al., 2006). Twelve homocysteinylated lysines were identified on 
all three chains of fibrinogen after incubation of isolated fibrinogen with Hcy thiolactone 
(Sauls et al., 2006). These fibrin clots showed fibers with decreased mass to length ratio 
and impaired fibrinolysis (Sauls et al., 2006). Further studies will be required to identify 
the mechanisms by which Hcy thiolactone affects fibrinogen, and how it relates to VTE.  
The effects of tyrosine nitration and oxidation on fibrinogen are discussed at length 
below. Briefly, several studies have demonstrated that tyrosine nitration increases fibrin 
clot formation (Parastatidis et al., 2008, Vadseth et al., 2004, Heffron et al., 2009, Gole et 
al., 2000). While tyrosine nitration is increased in VTE positive subjects compared to 
VTE negative subjects, no differences in tyrosine nitration were found between DVT and 
PE and it is thus unlikely to account for the differences in clot properties and structure. 
Oxidation of fibrinogen delays fibrin clot formation (Vadseth et al., 2004, Zieve and 
Solomon., 1966, Inada et al., 1978), but has yet to be evaluated in a VTE population. 
DVT and PE subjects both experienced elevated levels of nitrated fibrinogen. 
Consequently, oxidation is unlikely to account for differences between DVT and PE 
subjects since nitration negates the effects of fibrinogen oxidation (Vadseth et al., 2004).  
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Factor XII (FXII) is one of the initial mediators of the intrinsic pathway of the 
coagulation cascade, becoming activated (FXIIa) upon exposure to a damaged surface 
(Figure 1-1). FXIIa also directly interacts with fibrinogen during clot formation, resulting 
in dose-dependent delays in lag time and an increase in fiber density (Konings et al., 
2011). Polyphosphate is a linear polymer of inorganic phosphate that is stored in platelet 
dense granules and released upon platelet activation (Ruiz et al., 2004). Polyphosphate 
interacts with fibrin to produce thicker fibers, a stiffer clot structure, and delays in lysis, 
which were independent of FXIIIa crosslinking (Smith and Morrissey., 2008). Fibrin 
interactions with FXIIa, polyphosphate, or other plasma constituents have yet to be 
evaluated between DVT and PE, but may have important consequences for clot structure 
and tendency to embolize. 
4.1.5 Shear rates may affect embolization in proximal veins 
Given the increased propensity for embolization in proximal but not distal vein 
thrombosis, it is possible that different factors affect local thrombus formation. One 
obvious effector might be shear stress, which is related by the formula       
 
 
  
where τ is shear stress, µ is viscosity, u is velocity, and δ is the diameter of the vessel. As 
the blood is pumped back towards the heart from the lower veins through the upper veins, 
vessel segments enjoin and diameter increases. Thus far, no studies have compared shear 
stress in the proximal versus distal veins. However, using the formula above, if velocity 
and viscosity remain constant while diameter increases due to vessel enjoining, vascular 
shear stress should be reduced. Stasis or reduced shear rate is known to cause expression 
of adhesion molecules, recruitment of proinflammatory mediators, and secretion of 
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coagulation factors (Parmar et al., 2006). These local effectors may thus influence clot 
formation or propagation, increasing the tendency to embolize.  
4.1.6 Future directions 
VTE is a thrombotic disorder that has been thought to progress via endothelial cell 
activation, the recruitment of leukocytes, activation of the coagulation cascade followed 
by the production of fibrin, and also interactions with platelets (von Bruhl et al., 2012). 
Chapter 2 describes differences in fibrin clot structure and functional properties in DVT 
and PE subjects, with the goals of further understanding embolization. However, the 
coagulation cascade and the production of fibrin are only one component in a complex 
processes involving many cell types that play important roles in mediating thrombosis. 
Furthermore, fibrin(ogen)-cellular interactions may have consequences for not only fibrin 
clot structure, but possibly embolization. Endothelial cells produce tissue factor when 
activated, ultimately resulting in the production of the prothrombinase complex for the 
cleavage of fibrinogen to fibrin (Grabowski et al., 1993, Campbell et al., 2009). 
Fibrinogen co-cultured with TNFα-activated endothelial cell monolayers display fibrin 
clot structures that have increased fiber density close to the cells that diminishes with 
increasing distance (Campbell et al., 2009). Heterogeneity in fibrin clot structure may 
alter lysis rates, where tPA and plasmin lyse clots faster at the periphery and 
progressively decrease in speed towards the core. Increased fiber density towards the 
endothelium may provide stability during clot formation, whereas clots created by diffuse 
tissue factor production may result in clots with diminished fiber density, making them 
liable for embolization. Although the direct interaction of neutrophils and monocytes 
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with fibrinogen and the resultant effects on clot structure have yet to be determined, 
addition of neutrophils prior to clot formation decreased lag time while also diminishing 
clot strength (Perrin et al., 2008). In addition, proteins derived from activated neutrophils 
such as lysosomal cationic protein, enhanced lateral aggregation of fibrin protofibrils, 
increasing fiber diameter (Carr et al., 1986). Thus, variations in local leukocyte 
concentration or the proteins that they secrete during activation may influence fibrin clot 
structure and stability. Although the interactions between fibrinogen and platelets have 
been well studied, their effects on clot structure or embolization are unknown. 
Classically, fibrinogen binds to αIIbβ3 on platelets, creating bridges that bind platelet 
together (Marguerie et al., 1979). In venous thrombosis, platelets directly interact with 
both the endothelium and leukocytes (von Bruhl et al., 2012). Platelet-leukocyte 
interactions promote leukocyte recruitment and the releases of neutrophil extracellular 
traps (NETs), which are extracellular chromatin fibers and histones that function in this 
setting to concentrate procoagulant mediators like tissue factor and FXIIa (von Bruhl et 
al., 2012). Fibrin is also concentrated at the NETs, and it remains to be determined what 
effects this may have on fibrin clot structure. Again, the concentration of initiating 
coagulation factors near the endothelial cell surface could alter fibrin clot density, 
ultimately affecting thrombus stability. 
Ideally our studies on clot structure in DVT and PE would be extended to an in vivo 
model of thrombosis, where all cellular and plasma constituents are present. One possible 
model might involve the use fibrinogen deficient (Fg
-/-
) mice (Iwaki et al., 2002). 
Fibrinogen isolated from either DVT or PE subjects would be fluorescently tagged and 
injected into Fg
-/-
 mice. Thrombosis would be initiated by a method that does not denude 
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the endothelium such as electrical stimulation, and time to thrombus formation, lysis, and 
the number of emboli formed could be evaluated by intravital microscopy. In addition, 
fibrin clot structure and thrombus cellular composition could be evaluated by SEM and 
procoagulant factors and inflammatory mediators could be measured by histology. 
Another approach to evaluate the in vivo structure of DVT and PE thrombi would be to 
obtain thrombi via either thrombectomy or embolectomy during the course of treatment 
or during necropsy. Ideally, thrombi would be collected from distal DVT, proximal DVT, 
and PE for a comparison of clot structure and cellular composition during changes in the 
propensity for embolization. Although no study has evaluated in vivo thrombi between 
DVT and PE patients, some studies have evaluated each separately. Early studies 
evaluating the structures of 50 valve-pocket thrombi from the femoral veins of 41 post-
mortem subjects observed heterogeneity amongst the thrombi collected (Sevitt., 1974). 
Some thrombi had little or no cellular invasion. Most others had two main regions, red 
areas composed of fibrin and erythrocytes representing the initiating point, and white 
areas composed mainly of platelets and fibrin(ogen) representing sites of thrombus 
propagation. Thrombus structure has also been evaluated in one PE patient undergoing 
embolectomy (Undas et al., 2010). Although there was no comparison group, the 
thrombus obtained during embolectomy was in itself heterogeneous, with the inner 
thrombus composed of tightly packed thick fibrin fibers and cellular debris, likely from 
erythrocytes, and the periphery was composed of many erythrocytes in a thin fibrin 
network with few platelets. The authors did not observe the characteristic layering of 
‘white’ and ‘red’ thrombi that has been previously described for venous and arterial 
thrombi (Sevitt., 1974, Silvain et al., 2011). These data may indicate that not only fibrin 
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clot structure, but also cellular constituents may have an effect on propensity for 
embolization.  
4.2 Nitrated fibrinogen is a biomarker for VTE 
VTE is a thrombotic disease where thrombus initiation is characterized by the recruitment 
of inflammatory mediators including neutrophils, monocytes and cytokines (von Bruhl et 
al., 2012). Neutrophils contain myeloperoxidase (MPO), which is capable of generating 
nitrative intermediates (van der Vliet et al., 1997). Previous studies in models of 
inflammatory challenge, coronary artery disease, and smokers have found fibrinogen to 
be post-translationally modified by reactive nitrogen intermediates, creating nitrated 
fibrinogen. Despite the relationship between oxidant production, inflammation, and 
thrombosis in VTE, no specific markers encompassing these processes has been 
identified. The goal of this study was to evaluate nitrated fibrinogen as a biomarker of 
VTE. The study population consisted of subjects presenting with symptoms of VTE to 
the emergency department at the Hospital of the University of Pennsylvania. Nitrated 
fibrinogen levels were significantly elevated in the plasma of subjects that were found to 
be positive for acute DVT or PE. Cubic spline analysis demonstrated a positive 
relationship between nitrated fibrinogen levels and odds of VTE. When divided into 
quartiles, subjects in the highest quartile of nitrated fibrinogen had increased odds of 
VTE compared to subjects in the lowest quartile. This relationship persisted after 
univariate regression analysis for those variables that were elevated in VTE positive 
subjects: advanced age, active cancer, and recent surgery. However, significance was lost 
when the three variables were combined in multivariate regression analysis. These data 
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support a role for inflammation and oxidant production in VTE, and establish nitrated 
fibrinogen as a biomarker of these processes. 
4.2.1 Nitrated fibrinogen levels are elevated in VTE positive subjects 
Elevated nitrated fibrinogen levels in VTE positive subjects were not dependent on 
changes in plasma fibrinogen concentration as no differences were observed between 
VTE positive and negative subjects with either fibrinogen assay. Nitrated fibrinogen 
levels were higher in our VTE negative population than in previous studies where VTE 
subjects were compared to healthy controls (Parastatidis et al., 2008, Vadseth et al., 2004, 
Heffron et al., 2009). Our VTE negative group consisted of subjects that presented with 
symptoms of VTE, but were not found to have DVT by compression ultrasound (CUS) or 
PE by computed tomographic pulmonary angiography (CTPA). Many of the VTE 
negative subjects had previous history of coronary artery disease (CAD), smoking, 
infection, and other inflammatory conditions that likely affected nitrated fibrinogen 
levels. Because arterial thrombosis, smoking, infection etc. are risk factors for VTE and 
have been shown to produce nitrated fibrinogen (Parastatidis et al., 2008, Vadseth et al., 
2004, Heffron et al., 2009), this suggests that nitrative intermediates are produced both in 
VTE as well as in those at risk for disease and may ultimately contribute to disease 
pathogenesis. 
4.2.2 Nitrated fibrinogen is a risk factor for VTE 
Cubic spline curves demonstrated a strong, positive relationship between nitrated 
fibrinogen levels and odds of VTE. In addition, VTE positive subjects in the highest 
quartile of nitrated fibrinogen had an increased risk of VTE compared with those in the 
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lowest quartile. Regression analysis showed that this risk persisted after univariate, but 
not multivariate adjustment for the variables found to be elevated in the VTE positive 
group: advanced age, active cancer, and recent surgery. This suggests that those with 
advanced age, active cancer, and recent surgery also experience elevated nitrated 
fibrinogen levels independent of VTE. Indeed previous studies have documented elevated 
nitrated fibrinogen in lung cancer subjects (Pignatelli et al., 2001). Further studies 
evaluating nitrated fibrinogen in advanced age, recent surgery, and other cancer types 
will be necessary to address these findings. Alternatively, the loss of significance may be 
due to limited numbers within our subject population. Because the VTE positive subject 
group is relatively small, adjustment further reduces the sample size and eliminates 
statistical significance. Additional studies with a larger population size would be 
necessary to address this. 
4.2.3 Nitrated fibrinogen may affect clot formation in VTE 
Nitrated fibrinogen has been associated with both arterial thrombosis (Vadseth et al., 
2004), as well as those at risk for disease such as smokers (Parastatidis et al., 2008). 
Neutrophils and monocytes, which are capable of producing nitrating intermediates, are 
key mediators in the initial phases of venous thrombus formation (von Bruhl et al., 2012, 
Kakkar et al., 1969, Brennan et al., 2002, Hazen et al., 1999). Furthermore, nitrated 
fibrinogen levels increase in response to inflammation (Heffron et al., 2009). The effects 
of nitrated fibrinogen remain to be elucidated for VTE, however previous studies have 
investigated these effects in vitro (Vadseth et al., 2004) and ex vivo in the plasma of 
smokers (Parastatidis et al., 2008). When fibrinogen was nitrated with either 3-
morpholinosydnonimine (SIN-1), which produces nitric oxide and superoxide
 
that react 
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to form peroxynitrite, or with MPO, hydrogen peroxide, and nitrite, a decrease in lag time 
and an increase in both the rate of fibrin polymerization and final absorbance was 
observed during turbidity assays when compared with unmodified fibrinogen (Vadseth et 
al., 2004). Fibrinogen treated with MPO and hydrogen peroxide alone i.e. oxidizing 
conditions, produced impairment of fibrin polymerization. Furthermore, oxidized 
fibrinogen that was subsequently nitrated resulted in a reversal of the impaired fibrin 
polymerization, producing polymerization rates similar to nitration alone. The clot 
structure formed from nitrated fibrinogen is composed of thick, twisted fiber bundles and 
large pores, which is in contrast to the homogenous structure composed of thin fibers 
created from fibrinogen treated with MPO and hydrogen peroxide. Although nitration and 
oxidation of fibrinogen produce disparate effects on clot structure, G’ was similar 
between the two groups and significantly lower than control, indicating a decrease in clot 
stiffness. Although no differences in lysis rate or lysis product formed were seen between 
control and nitrated fibrinogen in vitro, injection of microemboli into mice composed of 
fibrin treated with SIN-1 followed by bolus injection of tPA showed enhanced lytic 
susceptibility compared to emboli of nascent fibrin. No differences were observed 
between nitrated and control fibrinogen for fibrinopeptide A (FpA) or B (FpB) release or 
FXIIIa crosslinking.  
In smokers, elevated nitrated fibrinogen levels showed a dose-dependent increase in the 
rate of fibrin polymerization that was reversed when nitrated molecules were removed via 
immunoprecipitation with antinitrotyrosine antibodies (Parastatidis et al., 2008). 
Scanning electron micrographs showed fiber clustering that was also reversed by 
antibody immunoprecipitation. Nitrated fibrinogen levels were positively correlated with 
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G’, G”, tan δ, and inversely correlated with fibrinolysis rate. Mass spectrometric analysis 
revealed Tyr
292
 and Tyr
422
 as nitrated in a majority of the samples analyzed. These 
residues are located in the carboxy terminus of the β chain of fibrinogen near the ‘b’ hole. 
Use of the ‘B’ knob mimetic peptide accelerated lateral aggregation in all samples, but 
was positively correlated with nitrated fibrinogen levels. The effects of in vivo nitration in 
smokers show some similarities to the in vitro modified fibrinogen, such as increased rate 
of fibrin polymerization. However, there are some disparities between the two studies 
(G’, G”, tan δ, clot structure) that might be related to the particular tyrosines that are 
susceptible to nitration or the extent of nitration in each system. In this study, nitrated 
fibrinogen levels were positively correlated with Clauss-measured fibrinogen levels. 
Because Clauss measures fibrinogen based on clotting, this correlation may suggest that 
fibrinogen from VTE positive subjects also exhibits gain of function effects for fibrin 
polymerization due to nitration. However, VTE subjects might also exhibit unique 
functional properties and clot structures that are related to the selectivity and extent of the 
tyrosines that are nitrated. 
Many of the same pathways that produce nitrating intermediates also produce reactive 
oxygen intermediates. Reactive oxygen intermediates have been implicated in vascular 
disease pathology and hence, much attention has been paid to the role and function of 
oxidative modifications of coagulation factors, especially fibrinogen. In contrast to 
nitration, oxidation of fibrinogen by hematoporphyrins, photosensitive dyes, and 
chloramines, which release singlet oxygen (
1
O2), impair fibrin polymerization in a dose-
dependent manner (Zieve and Solomon., 1966, Inada et al., 1978). Photooxidized fibrin 
monomer does not bind fibrinogen as well as nascent fibrin monomer, despite similar 
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release of FpA and FpB (Inada et al., 1978). His16, which is located within the ‘B’ knob 
site of the Bβ chain of fibrinogen was the only amino acid found to be modified upon 
oxidation (Shimizu et al., 1986).  Oxidation of fibrinogen also has functional effects on 
lysis.  Pro-urokinase is activated faster in the presence of oxidized fibrin, and plasmin 
lyses oxidized fibrin at a faster rate. This implies a pro-fibrinolytic capacity for oxidized 
fibrinogen (Stief., 1993). Overall, the effect of oxidation on fibrinogen appears to be a 
loss of function, rather than gain of function as seen with nitration. Nitration levels were 
similar between DVT and PE in this study, but oxidation of fibrinogen in VTE has yet to 
be determined. Nonetheless, oxidation is unlikely to account for fibrin clot structure and 
functional property differences observed between DVT and PE subjects. Because both 
DVT and PE patients have elevated nitrated fibrinogen levels, the effect of nitration on 
fibrin clot structure and functional properties are likely supersede the effects of oxidation 
(Vadseth et al., 2004).  
4.2.4 Plasma fibrinogen levels are not associated with VTE 
Elevated plasma fibrinogen levels are a risk factor for CAD and its associated morbidity 
and mortality (Benderly et al., 1996, Folsom et al., 1997). Some studies have suggested a 
similar role for fibrinogen in VTE (Koster et al., 1994). Compared to healthy control 
subjects, fibrinogen levels measured by Clauss assay were significantly higher in DVT 
subjects, and were thus identified as a risk factor for DVT (Koster et al., 1994). However, 
later studies in the same subject population showed that fibrinogen was only a risk factor 
for DVT in subjects >45 years of age (van Hylckama Vlieg and Rosendaal., 2003). 
Conversely, in PE subjects, plasma fibrinogen levels were found to be lower compared to 
 85 
healthy controls (Kucher et al., 2003b, Kucher et al., 2003a). Plasma fibrinogen levels in 
this study population were similar between VTE positive and negative subjects, and 
between DVT and PE. Discrepancies between this study and others may be due to overall 
differences in subject population (Kucher et al., 2003b, Kucher et al., 2003a), or to 
differences in the comparison group, where DVT was compared to healthy age and sex-
matched controls (van Hylckama Vlieg and Rosendaal., 2003). 
4.2.5 Future directions 
D-dimer levels were significantly elevated in VTE positive compared with VTE negative 
subjects.  At an exclusionary cutoff of 0.5 µg/ml, sensitivity and specificity for D-dimer 
in this population were 100 % (95 % CI 91.6-100) and 22.3 % (95 % CI 16.1-29.6), 
respectively. D-dimer remains the standard non-invasive biomarker for diagnosis of acute 
DVT and PE due to its high sensitivity, especially in ELFA and ELISA-based tests (77-
100 %) (Di Nisio et al., 2007). However, specificity of D-dimer, regardless of test 
employed, remains lower and more variable (7-94 %) (Di Nisio et al., 2007). Lack of 
specificity for D-dimer requires that many patients undergo unnecessary imaging, which 
is both costly and also exposes patients to ionizing radiation in the case of CTPA and 
possibly allergy to the contrast agent (Lensing et al., 1990). Identification of a novel 
biomarker with specificity to VTE could greatly reduce these concerns. Attempts have 
been made to identify such markers. Prothrombin is activated to thrombin by the cleavage 
of prothrombin fragment 1+2 (PF 1+2) by the prothrombinase complex containing factors 
Xa and Va, Ca
2+
, and phospholipids. In a study that enrolled 135 consecutive outpatients 
with suspected lower extremity DVT, sensitivity of PF 1+2 was 100 %, but specificity 
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was only 11 % (Bozic et al., 2002). Similar results with high sensitivity and low 
specificity have been found for thrombin-antithrombin III complex, P-selectin, and 
VCAM-1 (Bozic et al., 2002). Thus the search remains ongoing for non-invasive 
diagnostic markers. Recently, 50 potential biomarkers were evaluated in 304 consecutive 
subjects presenting with VTE, 22 of which were positive (Nordenholz et al., 2008). Of 
the 50 proteins identified, only D-dimer, c-reactive protein (CRP), and MPO were 
potential markers. Further analysis found that MPO in combination with D-dimer did not 
increase sensitivity (100 %), but did increase specificity from 59 % to 73 %, which would 
have reduced the need for vascular imaging by 13 % (Mitchell et al., 2008). Due to our 
small sample size, we did not perform receiver operating characteristic curves or 
calculate sensitivity and specificity. However, the identification of MPO as a possible 
marker of VTE supports a role for inflammatory and oxidant markers in the diagnosis of 
VTE. Our observation that nitrated fibrinogen is a risk factor for VTE may lend itself to 
larger studies, pursuing it as a diagnostic marker, possibly in combination with D-dimer 
or MPO. 
Further evidence for the production of reactive nitrogen intermediates during 
inflammation comes from the identification of antibodies that recognize nitrated epitopes 
in atherosclerotic lesions and the circulation of CAD patients, as well as in plasma from 
acute lung injury patients (Thomson et al., 2007). Furthermore, antigen presenting cells 
display nitrated peptides by MHC class II molecule I-A, eliciting a CD4 T-cell response 
(Herzog et al., 2005). Although these processes have yet to be evaluated in VTE, the 
recognition of nitrated fibrinogen by antinitrotyrosine antibodies and the subsequent 
presentation of nitrated epitopes in VTE may represent a novel interplay between oxidant 
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production, inflammation, and thrombosis that has not yet been explored. In patients 
undergoing vein stripping for primary varicosity, dendritic cells, which are antigen 
presenting cells, were observed in patients with varicose veins and/or superficial 
thrombophlebitis, but not in vein segments from healthy subjects (Cherian et al., 1999). 
Dendritic cells were localized with T-cells and macrophages around areas of 
neovascularization. Although this study was performed in superficial thrombophlebitis 
and varicose veins, both of these conditions are risk factors for VTE (Heit et al., 2000b, 
Decousus et al., 2010). In addition, neovascularization subsequent to thrombosis has also 
been observed in a rat model of DVT (Wakefield et al., 1999) and it is probable that 
similar innate and adaptive immune responses occur for thrombus resolution in DVT. 
Thus, it is possible that nitrated fibrinogen is recognized by antibodies and targeted for 
antigen presentation in VTE, resulting in recruitment of adaptive immune cells for 
thrombus resolution. Additional studies would be required to address this. 
4.3 Risk factors for VTE  
Many variables have been associated with risk of VTE including patient demographics, 
disease history, and medication use.  Previous studies have shown that the risk of VTE 
increases exponentially as a function of age, with a relative risk of 1.9 per 10 year 
increase (Anderson et al., 1991). In accordance with these and other findings, VTE 
positive subjects in this study were older (Table 3-1) and no differences in age were 
observed between DVT and PE.  In our subject population males were significantly more 
prevalent in DVT subjects, whereas females were more prevalent in PE subjects. 
Tormene et al. similarly showed that men were at higher risk of isolated DVT and women 
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at higher risk of PE (Tormene et al., 2009). However, other studies indicate that DVT is 
more prevalent in women and PE in men (Kniffin et al., 1994), while others show no 
differences in prevalence between sexes (Anderson et al., 1991, Silverstein et al., 1998). 
Thus far it appears that the relationship between sex and risk for either DVT or PE 
remains unresolved. 
DVT subjects within our population had an increased incidence of peripheral artery 
disease compared with PE, despite being a risk factor for both DVT and PE (Sorensen et 
al., 2009, Sorensen et al., 2011).  In a population based study, subjects with a history of 
arterial thrombotic events including myocardial infarction and stroke were at risk for 
VTE three months following an event (Sorensen et al., 2009, Sorensen et al., 2011).  A 
recent study also suggests that heart disease is an independent risk factor for PE in the 
absence of venous thrombosis and suggests that PE might also arise from the heart itself 
rather than the venous system.  If this is the case, clots from these subjects might share 
structural characteristics that are similar to arterial clots.  Arterial and venous thrombotic 
diseases appear to share some, but not all clot structural characteristics (Collet et al., 
2006, Undas et al., 2009) and elucidating differences may help identify factors that 
uniquely contribute to each disease, and possibly embolization.  
In a cohort of 625 cases of VTE with age and sex-matched controls, malignant neoplasm 
increased risk of VTE by 4-fold, with a more than 6-fold increased risk for subjects on 
chemotherapy (Heit et al., 2000b).  In that same study, surgery increased the risk of VTE 
by more than 22-fold (Heit et al., 2000b).  Increased incidence of both cancer and surgery 
were found for VTE positive subjects in this study (Table 3-1), and incidences were 
similar between DVT and PE.  The use of immunomodulatory agents including 
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chemotherapeutics are implicated as risk factors for VTE.  In a landmark study (Levine et 
al., 1988), stage II breast cancer subjects were randomized to either 12 weeks of multi 
drug chemotherapy regimen that included cyclophosphamide, methotrexate, fluorouracil, 
vincristine, prednisone, doxorubicin plus tamoxifen or a similar 36 week regimen minus 
tamoxifen. During the course of treatment, 5 and 9 subjects developed VTE during the 
course of either the 12 or 36 week treatment, respectively (Levine et al., 1988). No 
thrombotic events occurred before or after the treatment course, implicating a direct 
relationship between chemotherapeutics and VTE. Research has also indicated that 
treatment of multiple myeloma with either thalidomide or lenalidomide coupled with 
dexamethasone increases rates of VTE (Dimopoulos et al., 2007, Rajkumar et al., 2006).  
Several subjects in this study reported taking immunomodulators such as prednisone, 
vincristine, fluorouracil, lenalidomide and dexamethasone. Although use of 
immunomodulators increases risk of both DVT and PE, in our study DVT subjects 
reported a higher use of these agents. Previous studies have indicated that hormonal 
contraception or hormone replacement therapies containing estrogen-derivatives are risk 
factors for VTE (Gerstman et al., 1990, Daly et al., 1996).  In our population, incidences 
of hormonal contraception or replacement therapy were similar between VTE negative 
and positive subjects and between DVT and PE.  
4.4 VTE, antioxidants, and pharmaceutics 
Several medications including anti-platelet therapies, statins, and antioxidants that are 
used in the treatment of arterial diseases, such as CAD, have also been effective at 
reducing the risk of VTE. The effects of these medications may be in part due to lowering 
oxidant burden in diseased patients. Given as a prophylactic to hip fracture surgery, 
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aspirin lowers the risk of a first DVT by 29 % and PE by 43 % compared with placebo 
(Anonymous 2000). Aspirin also attenuates lipid peroxidation and cytotoxicity of bovine 
aortic endothelial cells caused by SIN-1-oxidized low-density lipoprotein (Hermann et 
al., 1999). Statin use in females reduces the risk of VTE events compared to non-statin 
users (relative hazard=.45; P=0.02), and offsets the use of hormone replacement therapy 
(relative hazard=1.34; P=0.45) (Herrington et al., 2002). In an interventional study statins 
were given to subjects with borderline high (>130 mg/dL) cholesterol for 12 weeks and 
nitrotyrosine levels were measured prior to and after statin therapy. Levels of 
nitrotyrosine decreased by 25 % following statin use, and were similar in magnitude to 
reduction in total cholesterol and low-density lipoprotein particle number (Shishehbor et 
al., 2003).  The Women’s Healthy Study evaluated the effects of the antioxidant vitamin 
E on VTE by randomizing 39,876 women to 600 IU of vitamin E or placebo and 
followed them over 10 years (Glynn et al., 2007). Compared to placebo, vitamin E 
reduced relative hazard of VTE by 21 %. Antioxidant supplementation of 100 IU/kg 
vitamin E and 1 g vitamin C daily diminished neovascularization of the myocardium, 
reduced VEGF expression and reduced the amount of nitrotyrosine containing proteins in 
hypercholesterolemic pigs (Zhu et al., 2004). Although antiplatelets, statins, and 
antioxidant usage were similar between VTE negative and positive subjects, and between 
DVT and PE subjects in our cohort, future studies may investigate the relationships 
between these medications and their effects on oxidant burden and disease outcome. 
In conclusion, these studies show that fibrin clot structure and functional properties differ 
between DVT and PE subjects and provide further insight on the mechanisms that govern 
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embolization. These studies also identify nitrated fibrinogen as a unique biomarker of 
thrombosis, oxidant production, and inflammation in VTE. 
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